

Table 1. Proportion of Beneficiaries With and Without Cancer Diagnosis Prior to First Biologics Order Among Beneficiaries Satisfying a Period of Continuous AB FFS Enrollment Prior to First Relevant Claim by Class of Drug, Active Ingredient, and Period of Continuous Enrollment, 2006-2009

Note: An asterisk (*) signifies a small cell count (less than 11).

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim												
			No Cancer Diagnosis	140.x to 149.x	150.x to 159.x	160.x to 165.x	170.x to 176.x	179.x to 189.x	190.x to 199.x	200.x to 208.x	209.x	210.x to 229.x	230.x to 234.x	235.x to 238.x	239.x
Biologic response modifiers	Aldesleukin	1 month	7.3	*	9.5	13.1	41.9	37.7	56.0	7.2	*	6.2	4.9	10.6	7.2
Biologic response modifiers	Aldesleukin	3 months	6.9	1.9	10.9	15.0	43.5	39.0	61.3	9.3	*	13.8	6.8	17.9	14.1
Biologic response modifiers	Aldesleukin	6 months	6.2	2.5	14.2	17.0	46.1	39.5	66.4	11.1	*	22.3	10.2	26.5	19.1
Biologic response modifiers	Aldesleukin	12 months	5.2	2.6	18.4	19.8	48.5	39.8	68.8	13.5	*	33.3	14.8	36.1	27.8
Biologic response modifiers	BCG	1 month	1.2	0.1	1.3	1.1	3.7	97.1	2.5	1.2	*	10.0	20.5	16.9	31.9
Biologic response modifiers	BCG	3 months	0.9	0.2	2.0	1.5	6.1	98.0	3.9	1.6	0.0	17.0	25.9	26.9	46.8
Biologic response modifiers	BCG	6 months	0.7	0.3	2.5	1.9	9.0	98.3	5.1	1.9	0.0	23.3	28.4	33.2	52.8
Biologic response modifiers	BCG	12 months	0.5	0.4	3.3	2.3	13.2	98.5	6.6	2.2	0.0	32.8	31.5	40.8	59.4
Biologic response modifiers	Denileukin	1 month	0.9	0.6	3.0	2.0	16.9	1.4	3.7	97.9	*	3.0	1.7	3.6	1.5
Biologic response modifiers	Denileukin	3 months	0.8	0.7	4.2	2.8	19.8	1.9	4.9	97.9	*	5.9	3.0	6.0	3.0
Biologic response modifiers	Denileukin	6 months	0.7	0.9	4.9	3.4	24.9	2.5	5.9	97.9	*	9.5	4.2	9.2	5.3
Biologic response modifiers	Denileukin	12 months	0.6	1.1	6.0	3.7	28.8	3.0	7.2	98.0	*	15.6	5.8	14.3	8.0
Kinase inhibitors	Dasatinib	1 month	2.8	*	3.0	0.9	6.1	1.4	4.9	93.7	*	4.2	1.2	11.2	1.8
Kinase inhibitors	Dasatinib	3 months	1.1	*	3.5	1.3	8.1	1.7	5.4	95.5	*	7.2	1.6	15.8	2.6
Kinase inhibitors	Dasatinib	6 months	*	*	4.2	1.8	10.2	2.0	6.8	96.3	*	12.0	2.3	20.9	4.1
Kinase inhibitors	Dasatinib	12 months	*	*	4.7	2.5	13.3	3.0	8.5	96.8	*	19.7	3.7	27.2	5.7
Kinase inhibitors	Erlotinib	1 month	0.8	1.5	20.1	81.9	9.3	3.0	56.4	2.6	0.2	6.4	6.3	8.0	11.4
Kinase inhibitors	Erlotinib	3 months	0.3	1.9	21.5	82.9	12.8	4.1	63.9	3.4	0.2	11.4	8.8	13.5	17.7
Kinase inhibitors	Erlotinib	6 months	0.3	2.3	23.1	83.4	16.4	5.0	69.4	4.3	0.2	17.5	11.4	19.4	23.6
Kinase inhibitors	Erlotinib	12 months	0.2	2.7	24.8	83.9	21.3	6.2	74.2	5.3	0.3	27.6	14.7	28.1	31.1
Kinase inhibitors	Everolimus	1 month	*	*	7.7	12.2	9.2	93.0	81.6	*	2.7	4.0	4.2	6.5	5.7
Kinase inhibitors	Everolimus	3 months	*	*	11.2	17.6	12.5	92.9	88.3	3.3	3.6	8.4	6.4	9.9	12.2
Kinase inhibitors	Everolimus	6 months	*	*	15.3	22.5	18.3	93.1	92.6	4.0	4.2	14.8	7.9	15.6	18.8
Kinase inhibitors	Everolimus	12 months	*	*	22.7	28.1	25.0	92.6	95.2	4.6	4.6	27.3	9.9	24.4	29.3

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim												
			No Cancer Diagnosis	140.x to 149.x	150.x to 159.x	160.x to 165.x	170.x to 176.x	179.x to 189.x	190.x to 199.x	200.x to 208.x	209.x	210.x to 229.x	230.x to 234.x	235.x to 238.x	239.x
Kinase inhibitors	Gefitinib	1 month	11.4	*	*	83.7	5.2	*	30.4	*	*	6.4	3.4	*	6.1
Kinase inhibitors	Gefitinib	3 months	3.8	*	*	92.4	9.8	*	37.3	*	*	9.2	6.0	5.1	9.5
Kinase inhibitors	Gefitinib	6 months	*	*	3.5	94.9	13.1	*	41.0	*	*	13.8	9.3	8.7	12.8
Kinase inhibitors	Gefitinib	12 months	*	*	5.5	96.9	19.5	3.8	49.3	*	*	17.1	14.7	16.8	20.6
Kinase inhibitors	Imatinib	1 month	10.8	0.4	18.8	2.0	17.3	2.3	12.4	60.1	0.2	8.0	1.7	23.8	8.3
Kinase inhibitors	Imatinib	3 months	4.6	0.5	22.7	2.5	21.2	3.2	15.6	65.2	0.3	13.6	2.5	30.8	12.6
Kinase inhibitors	Imatinib	6 months	2.4	0.6	24.6	2.9	24.2	3.8	17.9	67.3	0.4	19.5	3.2	35.9	15.7
Kinase inhibitors	Imatinib	12 months	1.8	0.8	26.2	3.5	27.7	4.7	20.1	68.2	0.4	27.6	4.6	42.9	19.7
Kinase inhibitors	Lapatinib	1 month	*	1.2	4.6	6.7	98.4	1.5	80.3	1.4	*	3.5	5.7	4.6	9.4
Kinase inhibitors	Lapatinib	3 months	*	1.6	6.3	9.5	98.7	2.2	86.4	1.9	*	6.8	8.3	6.8	14.2
Kinase inhibitors	Lapatinib	6 months	*	1.9	8.0	11.8	98.8	3.2	90.4	2.5	*	10.5	10.8	9.2	18.7
Kinase inhibitors	Lapatinib	12 months	*	2.6	10.9	16.8	99.1	4.6	93.4	3.8	*	17.2	16.2	13.8	25.5
Kinase inhibitors	Nilotinib	1 month	2.0	*	5.7	*	11.2	*	7.7	91.4	*	2.4	*	12.1	*
Kinase inhibitors	Nilotinib	3 months	*	*	6.7	*	13.0	*	9.8	93.0	*	6.1	*	17.8	2.0
Kinase inhibitors	Nilotinib	6 months	*	*	8.1	*	14.7	*	12.4	93.2	*	9.1	*	24.1	3.1
Kinase inhibitors	Nilotinib	12 months	*	*	9.0	2.9	18.2	3.3	14.5	93.5	*	15.7	3.1	31.8	5.3
Kinase inhibitors	Pazopanib	1 month	*	*	*	*	*	93.8	93.8	*	*	*	*	*	*
Kinase inhibitors	Pazopanib	3 months	*	*	*	*	*	93.6	93.6	*	*	*	*	*	*
Kinase inhibitors	Pazopanib	6 months	*	*	*	*	*	93.3	100.0	*	*	*	*	*	*
Kinase inhibitors	Pazopanib	12 months	*	*	*	*	*	92.3	100.0	*	*	*	*	*	*
Kinase inhibitors	Sorafenib	1 month	0.9	0.7	53.9	11.7	10.0	44.2	57.1	2.6	0.2	7.8	4.8	11.7	12.9
Kinase inhibitors	Sorafenib	3 months	0.5	1.0	56.2	14.8	12.6	45.1	64.1	3.5	0.2	14.6	6.7	19.0	19.9
Kinase inhibitors	Sorafenib	6 months	0.3	1.3	57.6	17.5	15.5	45.7	67.8	4.4	0.3	21.4	8.3	25.4	26.0
Kinase inhibitors	Sorafenib	12 months	0.2	1.6	59.3	20.7	18.6	46.3	70.7	5.1	0.3	30.4	11.2	34.1	33.3
Kinase inhibitors	Sunitinib	1 month	58.7	0.3	10.4	5.9	8.9	29.1	30.5	1.4	0.2	2.8	1.6	6.9	5.5
Kinase inhibitors	Sunitinib	3 months	58.1	0.4	12.2	7.8	10.9	29.8	34.0	1.7	0.3	5.4	2.4	10.4	9.1
Kinase inhibitors	Sunitinib	6 months	*	0.5	13.7	9.2	13.0	30.1	36.0	2.4	0.3	8.3	3.3	13.4	12.4
Kinase inhibitors	Sunitinib	12 months	*	0.6	15.2	10.8	15.2	30.5	37.7	3.2	0.3	12.5	4.4	17.8	16.5
Kinase inhibitors	Temsirolimus	1 month	65.2	*	3.2	5.5	3.2	31.2	26.7	2.4	*	1.6	1.3	2.2	2.7
Kinase inhibitors	Temsirolimus	3 months	65.1	0.5	4.3	7.2	4.3	31.4	29.0	2.7	*	3.3	1.8	3.8	4.0
Kinase inhibitors	Temsirolimus	6 months	*	0.7	5.3	8.7	5.7	31.9	31.0	2.9	*	5.3	2.3	5.3	6.3
Kinase inhibitors	Temsirolimus	12 months	*	0.8	7.2	10.4	7.9	32.1	32.6	3.6	*	8.9	3.6	9.4	9.7
Miscellaneous biologic nonblood products	Asparaginase	1 month	9.9	*	4.6	*	6.4	*	13.1	80.9	*	4.2	*	12.0	*
Miscellaneous biologic nonblood products	Asparaginase	3 months	9.7	*	6.4	5.2	10.9	4.9	18.0	80.2	*	10.9	*	17.2	4.9
Miscellaneous biologic nonblood products	Asparaginase	6 months	9.1	*	7.1	5.9	11.8	5.9	21.7	79.9	*	16.9	*	20.9	6.3

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim												
			No Cancer Diagnosis	140.x to 149.x	150.x to 159.x	160.x to 165.x	170.x to 176.x	179.x to 189.x	190.x to 199.x	200.x to 208.x	209.x	210.x to 229.x	230.x to 234.x	235.x to 238.x	239.x
Miscellaneous biologic nonblood products	Asparaginase	12 months	5.5	*	8.0	5.5	16.0	8.0	24.8	80.7	*	22.7	5.9	24.8	7.6
Miscellaneous biologic nonblood products	Octreotide acetate	1 month	25.7	0.7	45.9	8.9	8.6	5.2	39.6	6.7	4.5	8.8	4.0	13.6	8.4
Miscellaneous biologic nonblood products	Octreotide acetate	3 months	22.2	0.9	48.8	10.5	11.3	6.4	47.2	7.7	4.8	16.5	6.4	20.2	13.9
Miscellaneous biologic nonblood products	Octreotide acetate	6 months	19.1	1.0	50.8	11.8	14.4	7.4	51.7	8.5	5.0	24.6	8.6	26.3	18.5
Miscellaneous biologic nonblood products	Octreotide acetate	12 months	15.8	1.2	53.2	13.4	18.4	8.5	55.3	9.4	5.1	34.7	11.4	33.9	24.0
Miscellaneous biologic nonblood products	Pegaspargase	1 month	19.5	*	7.4	*	8.7	7.4	14.1	59.1	*	*	*	*	*
Miscellaneous biologic nonblood products	Pegaspargase	3 months	17.2	*	7.6	7.6	10.3	*	17.9	59.3	*	*	*	14.5	*
Miscellaneous biologic nonblood products	Pegaspargase	6 months	15.4	*	10.3	8.1	15.4	8.1	22.8	58.1	*	12.5	*	25.0	8.1
Miscellaneous biologic nonblood products	Pegaspargase	12 months	15.7	*	11.6	*	19.0	*	28.1	57.9	*	24.0	*	30.6	10.7
Monoclonal antibodies	Alemtuzumab	1 month	8.4	0.4	3.6	2.6	7.3	1.9	7.1	87.0	*	4.4	1.5	11.4	1.7
Monoclonal antibodies	Alemtuzumab	3 months	7.7	0.5	4.3	3.4	11.7	2.5	9.4	87.3	*	9.4	2.9	17.2	3.3
Monoclonal antibodies	Alemtuzumab	6 months	7.0	0.8	5.1	4.1	16.6	3.3	11.3	87.6	*	14.5	4.8	22.9	5.2
Monoclonal antibodies	Alemtuzumab	12 months	5.9	0.8	5.8	5.3	22.7	4.1	13.9	88.2	*	24.0	7.9	32.2	8.1
Monoclonal antibodies	Bevacizumab	1 month	63.5	0.3	15.5	9.9	8.0	3.1	20.8	1.4	0.1	5.2	2.2	4.2	3.4
Monoclonal antibodies	Bevacizumab	3 months	59.1	0.4	15.8	10.5	10.3	3.8	22.9	1.8	0.1	9.8	3.4	7.5	5.6
Monoclonal antibodies	Bevacizumab	6 months	54.3	0.5	16.1	11.0	12.9	4.3	23.9	2.2	0.1	14.7	4.5	10.9	7.4
Monoclonal antibodies	Bevacizumab	12 months	47.4	0.6	16.4	11.4	16.6	5.0	24.5	2.6	0.1	22.4	6.3	16.0	9.8
Monoclonal antibodies	Cetuximab	1 month	0.2	31.2	59.7	24.4	15.7	2.9	76.7	3.5	0.1	7.9	8.5	9.3	11.9
Monoclonal antibodies	Cetuximab	3 months	0.2	32.7	60.5	27.7	20.1	3.9	83.3	4.6	0.1	14.4	12.0	16.0	18.3
Monoclonal antibodies	Cetuximab	6 months	0.1	33.6	61.1	30.5	23.5	5.1	87.4	5.5	0.2	20.7	15.1	21.2	23.3
Monoclonal antibodies	Cetuximab	12 months	0.1	34.8	61.4	34.3	28.2	6.9	90.7	6.6	0.2	31.5	19.8	29.4	30.8
Monoclonal antibodies	Gemtuzumab	1 month	1.6	*	2.9	2.8	5.6	2.0	7.0	96.4	*	4.2	0.9	46.2	2.0
Monoclonal antibodies	Gemtuzumab	3 months	1.5	*	3.3	3.5	8.3	3.0	10.0	96.6	*	8.5	1.8	54.1	3.4
Monoclonal antibodies	Gemtuzumab	6 months	1.2	*	4.4	3.9	11.0	3.9	12.9	96.7	*	14.0	3.0	59.5	4.8
Monoclonal antibodies	Gemtuzumab	12 months	1.1	*	5.3	4.2	15.3	5.2	15.3	97.1	*	23.2	3.8	65.7	6.7
Monoclonal antibodies	Ibritumomab	1 month	18.7	*	5.2	2.5	10.5	1.6	9.0	70.2	*	7.5	2.1	7.7	2.9
Monoclonal antibodies	Ibritumomab	3 months	17.7	0.9	6.1	3.1	13.8	1.8	11.7	70.2	*	13.0	2.9	13.9	5.1
Monoclonal antibodies	Ibritumomab	6 months	15.8	1.4	6.9	3.9	17.9	2.5	14.9	70.4	*	18.5	4.4	19.4	8.3
Monoclonal antibodies	Ibritumomab	12 months	13.8	1.9	8.1	4.8	23.5	3.2	18.2	70.4	*	27.4	5.8	27.4	12.3
Monoclonal antibodies	Panitumumab	1 month	0.3	0.8	98.1	7.7	4.4	2.4	75.4	1.8	*	3.3	5.6	3.7	4.8

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim												
			No Cancer Diagnosis	140.x to 149.x	150.x to 159.x	160.x to 165.x	170.x to 176.x	179.x to 189.x	190.x to 199.x	200.x to 208.x	209.x	210.x to 229.x	230.x to 234.x	235.x to 238.x	239.x
Monoclonal antibodies	Panitumumab	3 months	0.3	0.9	98.2	11.4	6.9	3.9	83.4	2.4	0.3	6.7	7.8	6.3	8.1
Monoclonal antibodies	Panitumumab	6 months	0.3	1.2	98.3	14.8	10.0	5.3	89.1	3.2	0.4	11.4	9.7	10.2	12.4
Monoclonal antibodies	Panitumumab	12 months	*	1.5	98.3	21.0	14.9	8.0	94.1	4.3	0.4	21.3	15.1	17.6	20.2
Monoclonal antibodies	Rituximab	1 month	13.1	1.5	5.2	3.8	8.9	2.4	11.2	83.6	0.0	8.9	1.5	14.9	6.5
Monoclonal antibodies	Rituximab	3 months	11.6	1.9	6.4	4.6	12.6	3.2	14.0	84.0	0.0	15.5	2.6	21.8	9.9
Monoclonal antibodies	Rituximab	6 months	10.2	2.2	7.1	5.2	16.2	3.8	15.5	84.4	0.1	21.1	3.7	26.7	11.9
Monoclonal antibodies	Rituximab	12 months	8.4	2.5	8.0	5.8	21.1	4.5	17.3	85.0	0.1	29.5	5.6	32.9	14.4
Monoclonal antibodies	Tositumomab	1 month	57.1	*	*	*	3.0	*	4.5	42.5	*	3.1	*	4.7	1.2
Monoclonal antibodies	Tositumomab	3 months	56.4	*	1.1	1.1	5.1	*	6.8	43.1	*	5.2	1.2	8.3	2.7
Monoclonal antibodies	Tositumomab	6 months	*	*	2.0	1.5	8.0	1.1	8.5	43.6	*	9.3	2.1	11.3	4.5
Monoclonal antibodies	Tositumomab	12 months	*	*	2.7	2.4	11.4	1.6	11.1	44.4	*	13.9	3.7	14.8	6.7
Monoclonal antibodies	Trastuzumab	1 month	88.2	0.2	1.1	0.9	10.6	0.3	7.8	0.9	*	0.6	0.9	0.7	0.9
Monoclonal antibodies	Trastuzumab	3 months	88.3	0.2	1.3	1.2	10.5	0.4	8.6	1.0	*	1.1	1.5	1.3	1.4
Monoclonal antibodies	Trastuzumab	6 months	0.1	0.3	1.4	1.5	10.4	0.5	9.1	1.1	*	1.7	1.9	1.8	1.9
Monoclonal antibodies	Trastuzumab	12 months	*	0.3	1.6	1.7	10.4	0.6	9.4	1.2	*	2.7	2.3	2.4	2.4
Other immunomodulators	Bortezomib	1 month	1.0	0.5	2.4	2.2	10.7	1.8	23.2	97.8	0.0	5.9	1.5	13.8	3.6
Other immunomodulators	Bortezomib	3 months	0.8	0.7	3.1	2.9	14.8	2.5	28.1	97.9	0.1	10.5	2.4	19.2	5.6
Other immunomodulators	Bortezomib	6 months	0.7	0.8	3.8	3.4	18.9	3.0	31.8	98.1	0.1	15.6	3.5	24.6	7.6
Other immunomodulators	Bortezomib	12 months	0.5	1.1	4.8	4.2	24.8	4.0	36.6	98.2	0.1	24.0	5.2	32.0	10.6
Other immunomodulators	Interferon alfa-2B	1 month	5.9	0.5	4.2	2.9	20.6	65.7	17.6	7.2	0.2	9.4	16.5	14.8	17.1
Other immunomodulators	Interferon alfa-2B	3 months	4.9	0.9	5.1	3.7	23.0	66.8	21.9	8.3	0.2	17.5	22.3	24.7	27.1
Other immunomodulators	Interferon alfa-2B	6 months	4.2	1.1	5.9	4.4	25.4	67.4	24.0	9.0	0.3	24.8	26.2	32.7	34.1
Other immunomodulators	Interferon alfa-2B	12 months	3.5	1.3	7.0	5.3	28.5	68.4	26.1	9.5	0.3	35.1	31.0	42.2	42.9
Other immunomodulators	Interferon gamma-1B	1 month	79.0	*	4.0	3.0	5.3	1.7	3.8	4.3	*	4.3	1.7	4.3	1.7
Other immunomodulators	Interferon gamma-1b	3 months	74.2	*	4.5	3.9	7.0	2.1	6.0	4.5	*	7.9	2.5	6.0	2.5
Other immunomodulators	Interferon gamma-1b	6 months	67.5	*	5.0	4.6	9.1	2.3	7.7	5.0	*	13.6	3.7	10.1	4.8
Other immunomodulators	Interferon gamma-1b	12 months	57.5	*	5.1	5.1	11.2	2.6	8.6	4.5	*	20.8	4.3	15.0	6.8

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim												
			No Cancer Diagnosis	140.x to 149.x	150.x to 159.x	160.x to 165.x	170.x to 176.x	179.x to 189.x	190.x to 199.x	200.x to 208.x	209.x	210.x to 229.x	230.x to 234.x	235.x to 238.x	239.x
Other immunomodulators	Lenalidomide	1 month	1.7	0.4	1.7	1.6	8.6	1.6	16.7	78.7	*	4.8	1.4	32.5	2.3
Other immunomodulators	Lenalidomide	3 months	1.1	0.5	2.3	2.1	12.3	2.2	21.0	79.6	*	9.0	2.2	37.3	4.1
Other immunomodulators	Lenalidomide	6 months	0.7	0.7	3.0	2.6	16.1	2.8	24.6	80.2	*	14.2	3.0	41.9	5.8
Other immunomodulators	Lenalidomide	12 months	0.5	0.8	4.0	3.3	22.1	3.7	29.2	80.8	*	22.7	4.9	48.4	8.6
Other immunomodulators	Peginterferon alfa-2a	1 month	90.0	0.1	1.4	0.3	1.0	0.4	0.4	0.8	*	5.2	0.3	1.6	0.5
Other immunomodulators	Peginterferon alfa-2a	3 months	83.6	0.2	2.2	0.4	1.4	0.6	0.6	1.0	*	9.6	0.5	2.9	0.9
Other immunomodulators	Peginterferon alfa-2a	6 months	77.2	0.2	2.8	0.5	2.0	0.8	0.8	1.3	*	14.1	0.8	4.6	1.4
Other immunomodulators	Peginterferon alfa-2a	12 months	68.7	0.3	3.9	0.6	2.8	1.2	1.3	1.7	*	20.5	1.3	7.2	2.6
Other immunomodulators	Peginterferon alfa-2b	1 month	90.3	*	1.2	0.2	0.9	0.4	0.5	1.0	*	4.9	0.3	1.8	0.5
Other immunomodulators	Peginterferon alfa-2b	3 months	83.8	0.2	1.8	0.3	1.4	0.6	0.9	1.4	*	9.3	0.4	3.1	0.9
Other immunomodulators	Peginterferon alfa-2b	6 months	77.2	0.2	2.4	0.5	1.9	0.9	1.3	1.6	*	14.0	0.8	4.8	1.5
Other immunomodulators	Peginterferon alfa-2b	12 months	69.0	0.3	3.1	0.6	2.7	1.1	1.6	1.8	*	21.2	1.3	7.0	2.8
Other immunosuppressives	Cyclosporine	1 month	83.6	0.2	1.2	0.5	4.4	0.7	0.9	3.3	*	4.6	1.3	5.5	1.0
Other immunosuppressives	Cyclosporine	3 months	76.9	0.3	1.6	0.7	6.9	1.0	1.3	3.7	*	8.0	2.2	8.4	1.7
Other immunosuppressives	Cyclosporine	6 months	69.3	0.4	2.0	0.8	9.7	1.4	1.8	4.0	*	13.0	3.5	12.1	2.7
Other immunosuppressives	Cyclosporine	12 months	59.6	0.6	2.4	1.1	13.4	2.0	2.6	4.3	*	20.9	5.5	17.0	4.2

Table2. Cancer Condition Categories (CCs) With Descriptions

CC Number	CC Description
7	Metastatic Cancer and Acute Leukemia
8	Lung, Upper Digestive Tract, and Other Severe Cancers
9	Lymphatic, Head and Neck, Brain, and Other Major Cancers
10	Breast, Prostate, Colorectal, and Other Cancers and Tumors
11	Other Respiratory and Heart Neoplasms
12	Other Digestive and Urinary Neoplasms
13	Other Neoplasms
14	Benign Neoplasms of Skin, Breast, Eye

Table 3. Proportion of Beneficiaries With and Without Cancer Condition Category (CC) Prior to First Biologics Order Among Beneficiaries Satisfying Varying Periods of Continuous AB FFS Enrollment Prior to First Relevant Claim by Class of Drug, Active Ingredient, and Period of Continuous Enrollment, 2006-2009

Note: An asterisk (*) signifies a small cell count (less than 11).

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
			No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Biologic response modifiers	Aldesleukin	1 month	10.0	51.8	15.0	13.4	78.4	2.1	6.9	10.9	5.1
Biologic response modifiers	Aldesleukin	3 months	9.0	58.1	17.6	17.1	80.3	3.1	12.4	20.1	10.9
Biologic response modifiers	Aldesleukin	6 months	7.6	64.3	21.3	21.6	81.4	5.1	17.9	28.0	17.9
Biologic response modifiers	Aldesleukin	12 months	6.3	66.3	24.7	25.4	82.1	6.7	25.2	38.4	28.9
Monoclonal antibodies	Alemtuzumab	1 month	9.0	13.8	6.1	86.5	10.0	0.7	1.7	7.1	5.3
Monoclonal antibodies	Alemtuzumab	3 months	8.3	17.7	8.2	87.1	14.0	1.2	3.8	12.5	10.3
Monoclonal antibodies	Alemtuzumab	6 months	7.5	21.2	10.1	87.5	17.6	1.7	6.1	18.6	16.1
Monoclonal antibodies	Alemtuzumab	12 months	6.4	26.5	13.1	88.1	20.9	2.4	10.9	27.0	24.9
Miscellaneous biologic nonblood products	Asparaginase	1 month	6.0	77.4	7.1	59.4	21.9	*	*	4.6	*
Miscellaneous biologic nonblood products	Asparaginase	3 months	5.6	79.4	10.9	64.8	29.2		4.5	8.6	7.1
Miscellaneous biologic nonblood products	Asparaginase	6 months	4.7	79.5	11.8	67.3	34.6	*	7.5	12.2	11.0
Miscellaneous biologic nonblood products	Asparaginase	12 months	*	79.8	13.4	71.4	38.2	*	11.3	18.9	16.8
Biologic response modifiers	BCG	1 month	1.1	1.6	1.2	1.5	97.3	0.3	49.4	6.3	3.7
Biologic response modifiers	BCG	3 months	0.7	2.5	1.7	2.1	98.3	0.5	66.2	10.9	7.0
Biologic response modifiers	BCG	6 months	0.6	3.2	2.1	2.6	98.6	0.7	72.5	15.6	11.3
Biologic response modifiers	BCG	12 months	0.4	4.2	2.6	3.1	98.9	1.1	78.9	22.8	17.9
Monoclonal antibodies	Bevacizumab	1 month	62.9	18.4	11.6	4.4	23.7	1.5	3.8	4.2	4.0
Monoclonal antibodies	Bevacizumab	3 months	58.0	20.7	12.8	5.3	26.1	2.3	7.2	7.4	7.2
Monoclonal antibodies	Bevacizumab	6 months	52.8	21.8	13.5	5.9	28.0	2.9	10.2	11.0	11.3
Monoclonal antibodies	Bevacizumab	12 months	45.6	22.4	14.3	6.6	30.1	3.6	14.8	16.6	18.0
Other immunomodulators	Bortezomib	1 month	1.5	19.9	2.4	97.5	13.1	0.6	3.3	10.7	3.5
Other immunomodulators	Bortezomib	3 months	1.1	24.4	3.2	97.7	17.4	1.0	5.8	15.9	6.7
Other immunomodulators	Bortezomib	6 months	0.9	27.8	3.9	97.9	21.1	1.4	8.5	21.2	11.0
Other immunomodulators	Bortezomib	12 months	0.7	32.0	4.8	98.0	25.8	1.9	13.0	28.5	17.7
Monoclonal antibodies	Cetuximab	1 month	0.3	59.9	17.5	39.7	83.9	5.3	13.8	12.8	2.6
Monoclonal antibodies	Cetuximab	3 months	0.2	68.3	21.9	41.8	86.4	8.3	22.2	18.5	5.4
Monoclonal antibodies	Cetuximab	6 months	0.2	73.6	26.1	43.3	87.8	10.1	29.1	22.9	8.7
Monoclonal antibodies	Cetuximab	12 months	0.1	78.2	32.3	45.6	89.1	12.5	40.6	29.6	14.3
Other immunosuppressives	Cyclosporine	1 month	84.5	1.4	1.5	2.8	2.7	0.3	2.0	5.4	4.6

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
			No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunosuppressives	Cyclosporine	3 months	77.5	1.7	1.9	3.5	4.1	0.5	3.5	8.6	8.4
Other immunosuppressives	Cyclosporine	6 months	69.8	1.9	2.3	4.0	5.5	0.7	5.7	12.5	13.0
Other immunosuppressives	Cyclosporine	12 months	59.6	2.2	2.7	4.6	7.3	1.0	9.7	18.2	19.9
Kinase inhibitors	Dasatinib	1 month	4.5	20.5	84.5	31.0	8.0	*	2.3	3.9	3.6
Kinase inhibitors	Dasatinib	3 months	1.6	23.3	88.9	40.8	9.9	*	4.5	7.5	5.8
Kinase inhibitors	Dasatinib	6 months	*	26.6	90.5	50.1	12.2	*	6.6	11.0	9.3
Kinase inhibitors	Dasatinib	12 months	*	32.0	91.7	61.0	15.1	0.9	11.0	15.7	15.2
Biologic response modifiers	Denileukin	1 month	56.9	10.5	2.3	34.0	7.0	0.4	1.6	4.0	4.1
Biologic response modifiers	Denileukin	3 months	52.2	12.0	2.9	35.0	9.2	0.7	3.2	6.6	7.4
Biologic response modifiers	Denileukin	6 months	47.8	12.5	3.3	36.2	11.4	0.9	5.2	9.6	11.1
Biologic response modifiers	Denileukin	12 months	42.2	13.4	4.0	37.0	13.5	1.1	8.6	14.5	17.3
Kinase inhibitors	Erlotinib	1 month	1.1	50.7	96.0	9.0	22.1	9.8	6.1	5.8	2.5
Kinase inhibitors	Erlotinib	3 months	0.4	58.1	97.2	12.2	29.5	15.6	9.9	9.8	5.2
Kinase inhibitors	Erlotinib	6 months	0.3	63.4	97.5	15.1	36.0	21.4	13.8	14.3	8.9
Kinase inhibitors	Erlotinib	12 months	0.3	68.3	97.8	18.1	42.4	29.1	19.6	21.4	15.4
Kinase inhibitors	Everolimus	1 month	*	77.4	13.2	8.2	96.5	*	6.2	7.5	*
Kinase inhibitors	Everolimus	3 months	*	85.8	18.6	12.5	96.4	2.8	10.4	13.7	4.1
Kinase inhibitors	Everolimus	6 months	*	89.4	25.1	17.5	97.6	5.3	15.9	20.6	7.4
Kinase inhibitors	Everolimus	12 months	*	92.9	32.7	21.3	97.7	9.4	25.0	31.0	11.6
Kinase inhibitors	Gefitinib	1 month	15.0	24.5	79.1	4.9	9.2	5.5	*	3.7	3.4
Kinase inhibitors	Gefitinib	3 months	5.1	31.6	90.2	5.7	14.2	8.5	*	6.6	6.0
Kinase inhibitors	Gefitinib	6 months	.	34.6	92.9	8.3	18.9	13.5	*	9.9	8.3
Kinase inhibitors	Gefitinib	12 months	.	43.8	95.2	11.6	24.3	21.6	6.8	17.5	14.4
Monoclonal antibodies	Gemtuzumab	1 month	2.8	95.2	26.2	43.4	11.5	.	1.7	4.5	4.3
Monoclonal antibodies	Gemtuzumab	3 months	2.1	96.3	33.5	53.5	16.6	1.2	3.9	8.5	7.8
Monoclonal antibodies	Gemtuzumab	6 months	1.5	96.5	38.3	60.1	19.6	1.5	6.6	13.2	12.6
Monoclonal antibodies	Gemtuzumab	12 months	1.4	96.8	43.8	67.4	24.4	2.1	11.8	20.0	20.4
Monoclonal antibodies	lbritumomab	1 month	18.3	7.4	4.3	70.5	14.2	.	4.3	8.8	7.2
Monoclonal antibodies	lbritumomab	3 months	16.9	9.5	5.6	70.6	17.3	0.8	7.6	14.0	12.4
Monoclonal antibodies	lbritumomab	6 months	15.0	11.2	6.8	70.9	20.7	1.5	10.8	20.5	16.9
Monoclonal antibodies	lbritumomab	12 months	12.7	14.0	7.9	70.9	25.0	2.5	15.2	28.9	26.0
Kinase inhibitors	Imatinib	1 month	16.2	15.8	62.4	29.3	16.1	0.5	10.3	13.5	3.4
Kinase inhibitors	Imatinib	3 months	7.9	19.5	72.6	36.9	20.9	0.9	15.9	18.9	6.2
Kinase inhibitors	Imatinib	6 months	5.1	22.6	76.7	42.6	24.4	1.1	19.9	23.3	10.4
Kinase inhibitors	Imatinib	12 months	3.7	26.0	79.7	49.1	28.2	1.6	26.0	29.6	15.9
Other immunomodulators	Interferon alfa-2b	1 month	5.8	15.1	5.0	8.4	86.7	0.6	29.5	10.9	6.3
Other immunomodulators	Interferon alfa-2b	3 months	5.0	19.2	6.1	10.5	88.0	1.2	41.2	18.6	13.3

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
			No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Interferon alfa-2b	6 months	4.3	21.0	7.0	11.8	88.7	1.6	48.1	24.5	19.2
Other immunomodulators	Interferon alfa-2b	12 months	3.6	22.6	8.0	12.8	89.4	2.1	56.6	32.4	26.2
Other immunomodulators	Interferon gamma-1b	1 month	80.7	2.6	3.5	4.0	8.1	*	1.9	4.3	2.7
Other immunomodulators	Interferon gamma-1b	3 months	74.6	4.3	3.7	5.1	10.7	*	3.6	7.6	6.3
Other immunomodulators	Interferon gamma-1b	6 months	67.6	6.0	4.6	6.0	12.4	2.0	5.7	10.8	10.7
Other immunomodulators	Interferon gamma-1b	12 months	57.7	6.6	5.6	5.8	14.7	2.6	9.6	13.9	17.2
Kinase inhibitors	Lapatinib	1 month	0.8	76.7	6.1	7.7	98.2	0.5	1.3	11.0	6.2
Kinase inhibitors	Lapatinib	3 months	.	83.5	9.3	10.6	99.1	1.1	2.7	18.0	10.7
Kinase inhibitors	Lapatinib	6 months	.	87.9	12.1	13.4	99.5	1.8	3.8	24.5	16.7
Kinase inhibitors	Lapatinib	12 months	.	91.6	17.2	18.7	99.5	3.1	6.6	35.5	29.1
Other immunomodulators	Lenalidomide	1 month	17.7	16.2	2.4	76.5	10.1	0.4	2.3	8.2	3.3
Other immunomodulators	Lenalidomide	3 months	14.9	20.2	3.3	77.5	14.2	0.7	4.4	12.9	6.6
Other immunomodulators	Lenalidomide	6 months	12.9	23.6	4.1	78.0	17.9	1.1	7.1	17.7	10.4
Other immunomodulators	Lenalidomide	12 months	10.1	28.0	5.0	78.5	22.6	1.6	11.9	25.1	17.3
Kinase inhibitors	Nilotinib	1 month	3.1	19.4	88.3	29.3	9.1	*	2.0	6.6	2.0
Kinase inhibitors	Nilotinib	3 months	*	24.5	92.4	40.8	11.9	*	4.1	9.5	5.4
Kinase inhibitors	Nilotinib	6 months	*	28.4	93.8	49.6	15.1	*	6.4	13.1	9.1
Kinase inhibitors	Nilotinib	12 months	*	35.1	96.1	64.7	19.4	*	10.8	18.6	13.9
Miscellaneous biologic nonblood products	Octreotide acetate	1 month	25.1	34.2	27.8	9.8	55.7	1.7	13.5	9.2	2.6
Miscellaneous biologic nonblood products	Octreotide acetate	3 months	22.5	42.0	31.8	11.7	58.8	2.7	22.3	14.6	5.4
Miscellaneous biologic nonblood products	Octreotide acetate	6 months	20.1	46.6	34.9	13.4	61.1	3.7	30.0	19.9	9.5
Miscellaneous biologic nonblood products	Octreotide acetate	12 months	17.1	50.3	38.6	15.1	63.5	4.9	38.5	27.0	15.9
Monoclonal antibodies	Panitumumab	1 month	0.3	69.4	11.8	3.5	98.3	1.1	6.9	2.7	1.2
Monoclonal antibodies	Panitumumab	3 months	0.3	78.3	17.7	4.8	98.6	1.7	11.3	5.2	2.6
Monoclonal antibodies	Panitumumab	6 months	0.3	84.9	24.0	6.3	98.7	2.5	17.2	8.7	4.8
Monoclonal antibodies	Panitumumab	12 months	*	91.3	34.8	8.6	98.8	4.0	30.6	14.4	9.1
Kinase inhibitors	Pazopanib	1 month	*	87.5	*	*	96.9	*	*	*	*
Kinase inhibitors	Pazopanib	3 months	*	90.3	*	*	96.8	*	*	*	*
Kinase inhibitors	Pazopanib	6 months	*	96.7	*	*	100.0	*	*	36.7	*
Kinase inhibitors	Pazopanib	12 months	*	100.0	*	*	100.0	*	*	42.3	*
Miscellaneous biologic nonblood products	Pegaspargase	1 month	20.1	63.1	12.8	41.6	17.4	*	*	.	*
Miscellaneous biologic nonblood products	Pegaspargase	3 months	17.2	66.2	17.9	49.7	19.3	*	*	11.0	*

Class	Active Ingredient	Lookback Period of Continuous Enrollment	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
			No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Miscellaneous biologic nonblood products	Pegaspargase	6 months	15.4	68.4	21.3	52.9	25.0	*	*	18.4	14.0
Miscellaneous biologic nonblood products	Pegaspargase	12 months	15.7	68.6	22.3	57.0	28.9	*	9.9	23.1	20.7
Other immunomodulators	Peginterferon alfa-2a	1 month	90.4	0.2	1.1	0.9	1.4	*	3.5	1.7	2.2
Other immunomodulators	Peginterferon alfa-2a	3 months	83.9	0.3	1.6	1.2	2.1	0.1	6.8	3.0	4.0
Other immunomodulators	Peginterferon alfa-2a	6 months	77.7	0.4	2.1	1.6	2.9	0.3	9.7	4.6	6.4
Other immunomodulators	Peginterferon alfa-2a	12 months	69.0	0.6	2.7	2.0	4.0	0.5	14.1	7.6	10.3
Other immunomodulators	Peginterferon alfa-2a	1 month	90.4	0.4	0.9	0.9	1.5	*	3.5	1.6	2.2
Other immunomodulators	Peginterferon alfa-2a	3 months	83.4	0.7	1.3	1.4	2.4	0.2	7.0	2.7	4.3
Other immunomodulators	Peginterferon alfa-2a	6 months	76.6	0.8	1.8	1.7	3.2	0.4	9.9	4.7	7.1
Other immunomodulators	Peginterferon alfa-2a	12 months	68.1	1.0	2.4	2.1	4.1	0.5	14.6	7.7	11.2
Monoclonal antibodies	Rituximab	1 month	14.1	8.5	5.7	83.1	14.0	1.4	6.5	11.4	5.7
Monoclonal antibodies	Rituximab	3 months	12.6	10.6	7.1	83.5	18.0	2.2	10.7	18.1	10.7
Monoclonal antibodies	Rituximab	6 months	11.1	11.9	8.0	84.0	20.6	2.7	13.6	23.1	16.2
Monoclonal antibodies	Rituximab	12 months	9.1	13.5	9.0	84.6	23.7	3.3	18.2	30.0	24.1
Kinase inhibitors	Sorafenib	1 month	1.0	51.3	57.2	8.7	57.4	2.2	15.4	8.6	2.6
Kinase inhibitors	Sorafenib	3 months	0.4	58.7	60.7	11.5	60.8	3.6	24.3	14.3	5.4
Kinase inhibitors	Sorafenib	6 months	0.4	62.8	63.1	13.9	63.3	4.8	31.5	20.2	8.4
Kinase inhibitors	Sorafenib	12 months	0.2	65.6	66.4	16.0	65.1	6.5	40.3	27.8	14.3
Kinase inhibitors	Sunitinib	1 month	58.7	28.3	11.9	8.9	34.3	1.0	5.0	6.8	1.2
Kinase inhibitors	Sunitinib	3 months	58.0	32.0	14.9	10.4	35.8	1.9	8.0	10.4	2.3
Kinase inhibitors	Sunitinib	6 months	57.9	33.9	17.1	11.9	36.9	2.7	11.0	13.9	4.0
Kinase inhibitors	Sunitinib	12 months	57.7	35.9	19.3	13.9	38.2	3.7	14.9	18.2	6.9
Kinase inhibitors	Temsirolimus	1 month	65.2	25.0	5.2	5.0	32.4	0.8	2.1	2.7	0.9
Kinase inhibitors	Temsirolimus	3 months	65.1	27.7	7.2	6.0	32.9	1.1	3.4	4.4	1.9
Kinase inhibitors	Temsirolimus	6 months	64.8	30.2	9.3	6.9	33.6	2.1	5.3	6.9	2.8
Kinase inhibitors	Temsirolimus	12 months	64.5	32.0	11.7	8.5	34.0	2.9	8.2	11.4	5.6
Monoclonal antibodies	Tositumomab	1 month	56.9	2.9	0.9	42.6	4.6	*	1.2	3.7	1.5
Monoclonal antibodies	Tositumomab	3 months	56.2	4.8	1.3	43.2	6.2	*	2.4	6.9	4.2
Monoclonal antibodies	Tositumomab	6 months	55.7	5.7	2.2	43.7	8.0	1.0	4.2	11.3	7.3
Monoclonal antibodies	Tositumomab	12 months	54.8	8.3	3.2	44.5	10.6	1.3	6.7	16.3	11.0
Monoclonal antibodies	Trastuzumab	1 month	88.2	7.3	1.1	1.4	11.1	0.1	0.4	1.6	1.7
Monoclonal antibodies	Trastuzumab	3 months	88.3	8.1	1.4	1.7	11.1	0.2	0.7	2.6	3.1
Monoclonal antibodies	Trastuzumab	6 months	88.3	8.6	1.7	1.9	11.0	0.4	0.9	3.5	4.4
Monoclonal antibodies	Trastuzumab	12 months	88.4	9.0	2.0	2.2	10.9	0.5	1.4	4.5	5.5

Table 4: Proportion of Beneficiaries With and Without Cancer Condition Category (CC) Prior to First Biologics Order Among Beneficiaries Satisfying 6 Months of Continuous AB FFS Enrollment Prior to First Relevant Claim by Class of Drug, Active Ingredient, Age, Gender, and Race

Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = end stage renal disease. Rows with only small cells are omitted.

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Biologic response modifiers	Aldesleukin	Total	All	7.6	64.3	21.3	21.6	81.4	5.1	17.9	28.0	17.9
Biologic response modifiers	Aldesleukin	Age	Under 45	*	1.7	*	*	*	*	*	*	*
Biologic response modifiers	Aldesleukin		45 to 54	2.2	2.9	*	*	3.1	*	*	*	*
Biologic response modifiers	Aldesleukin		55 to 64	*	7.1	2.3	1.9	7.9	*	*	2.6	*
Biologic response modifiers	Aldesleukin		65 to 74	*	34.8	10.3	10.8	43.1	2.8	8.9	15.6	10.3
Biologic response modifiers	Aldesleukin		75 to 84	*	16.0	6.3	6.0	22.3	*	6.5	7.4	4.3
Biologic response modifiers	Aldesleukin		85 to 94	*	1.7	*	*	3.2	*	*	*	*
Biologic response modifiers	Aldesleukin	Gender	Male	4.2	44.2	15.3	13.1	56.1	4.2	12.5	20.3	10.9
Biologic response modifiers	Aldesleukin		Female	3.4	20.0	6.0	8.5	25.3	*	5.4	7.7	6.9
Biologic response modifiers	Aldesleukin	Race	White	4.8	58.1	17.4	19.3	73.3	4.5	15.7	26.8	16.3
Biologic response modifiers	Aldesleukin		Black	*	3.7	2.9	*	4.9	*	1.9	*	*
Monoclonal antibodies	Alemtuzumab	Total	All	7.5	21.2	10.1	87.5	17.6	1.7	6.1	18.6	16.1
Monoclonal antibodies	Alemtuzumab	Age	Under 45	2.3	*	*	0.5	*	*	*	*	*
Monoclonal antibodies	Alemtuzumab		45 to 54	1.4	*	*	2.0	*	*	*	*	*
Monoclonal antibodies	Alemtuzumab		55 to 64	1.1	1.6	1.1	6.6	1.4	*	0.4	0.9	0.9
Monoclonal antibodies	Alemtuzumab		65 to 74	1.6	10.0	5.3	42.0	8.1	0.9	2.9	8.5	7.5
Monoclonal antibodies	Alemtuzumab		75 to 84	0.8	7.7	2.8	31.1	6.6	0.4	2.4	7.4	5.9
Monoclonal antibodies	Alemtuzumab		85 to 94	*	1.4	0.7	5.2	1.1	*	*	1.5	1.2
Monoclonal antibodies	Alemtuzumab	Gender	Male	3.4	12.9	6.4	53.4	11.8	0.9	4.0	13.0	9.5
Monoclonal antibodies	Alemtuzumab		Female	4.1	8.3	3.7	34.0	5.7	0.7	2.2	5.6	6.6
Monoclonal antibodies	Alemtuzumab	Race	White	4.8	18.6	9.1	78.9	15.6	1.5	5.3	17.5	15.2
Monoclonal antibodies	Alemtuzumab		Black	2.2	1.9	0.8	7.2	1.8	*	0.6	0.9	0.8
Monoclonal antibodies	Alemtuzumab		Other	*	*	*	0.6	*	*	*	*	*
Monoclonal antibodies	Alemtuzumab		Hispanic	*	*	*	0.4	*	*	*	*	*
Miscellaneous biologic nonblood products	Asparaginase	Total	All	4.7	79.5	11.8	67.3	34.7	*	7.5	12.2	11.0

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Miscellaneous biologic nonblood products	Asparaginase	Age	Under 45	*	7.9	*	7.5	*	*	*	*	*
Miscellaneous biologic nonblood products	Asparaginase		45 to 54	*	4.7	*	4.3	*	*	*	*	*
Miscellaneous biologic nonblood products	Asparaginase		55 to 64	*	7.9	*	6.7	*	*	*	*	*
Miscellaneous biologic nonblood products	Asparaginase		65 to 74	*	43.3	6.7	37.4	18.1	*	4.7	6.7	5.5
Miscellaneous biologic nonblood products	Asparaginase		75 to 84	*	14.6	*	10.2	8.7	*	*	*	*
Miscellaneous biologic nonblood products	Asparaginase	Gender	Male	*	46.5	6.3	37.4	26.0	*	6.3	8.3	5.1
Miscellaneous biologic nonblood products	Asparaginase		Female	*	33.1	5.5	29.9	8.7	*	*	*	5.9
Miscellaneous biologic nonblood products	Asparaginase	Race	White	*	67.3	10.6	55.9	30.3	*	6.3	10.2	9.8
Miscellaneous biologic nonblood products	Asparaginase		Black	*	5.5	*	5.9	*	*	*	*	*
Biologic response modifiers	BCG	Total	All	0.6	3.2	2.1	2.6	98.6	0.7	72.5	15.6	11.3
Biologic response modifiers	BCG	Age	Under 45	0.0	*	*	*	0.1	*	0.1	*	*
Biologic response modifiers	BCG		45 to 54	0.0	0.0	*	*	0.5	*	0.4	0.1	0.0
Biologic response modifiers	BCG		55 to 64	0.0	0.1	0.1	0.1	2.3	0.0	1.7	0.2	0.2
Biologic response modifiers	BCG		65 to 74	0.2	1.0	0.7	0.8	34.9	0.3	25.7	4.8	3.6
Biologic response modifiers	BCG		75 to 84	0.2	1.6	1.0	1.3	45.6	0.3	33.6	7.8	5.6
Biologic response modifiers	BCG		85 to 94	0.1	0.5	0.3	0.4	14.7	0.1	10.7	2.7	1.8
Biologic response modifiers	BCG		95 and over	*	0.0	*	0.0	0.5	*	0.3	0.1	0.1
Biologic response modifiers	BCG	Gender	Male	0.3	2.5	1.6	2.0	76.9	0.6	56.5	12.8	8.5
Biologic response modifiers	BCG		Female	0.3	0.7	0.5	0.5	21.7	0.2	16.0	2.9	2.8
Biologic response modifiers	BCG	Race	White	0.5	3.0	2.0	2.4	93.4	0.7	68.7	15.1	11.1
Biologic response modifiers	BCG		Black	0.0	0.1	0.1	0.1	3.0	0.0	2.2	0.3	0.1

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Biologic response modifiers	BCG		Other	*	0.0	*	*	0.6	*	0.5	0.1	0.0
Biologic response modifiers	BCG		Asian	*	0.0	0.0	0.0	0.7	*	0.5	0.1	0.0
Biologic response modifiers	BCG		Hispanic	*	0.0	0.0	0.0	0.7	*	0.5	0.1	0.1
Biologic response modifiers	BCG		American Indian/Alaska Native	*	*	*	*	0.2	*	0.1	0.0	0.0
Monoclonal antibodies	Bevacizumab	Total	All	52.8	21.8	13.5	5.9	28.0	2.9	10.2	11.0	11.3
Monoclonal antibodies	Bevacizumab	Age	Under 45	0.2	0.2	0.1	0.1	0.3	0.0	0.1	0.1	0.0
Monoclonal antibodies	Bevacizumab		45 to 54	0.6	0.7	0.3	0.2	0.7	0.1	0.2	0.2	0.1
Monoclonal antibodies	Bevacizumab		55 to 64	1.6	1.5	0.8	0.4	1.5	0.2	0.5	0.4	0.3
Monoclonal antibodies	Bevacizumab		65 to 74	12.1	10.9	6.9	2.7	11.7	1.5	4.3	3.4	3.2
Monoclonal antibodies	Bevacizumab		75 to 84	22.6	7.3	4.8	1.9	10.5	1.0	4.1	4.6	5.0
Monoclonal antibodies	Bevacizumab		85 to 94	14.6	1.1	0.7	0.6	3.2	0.2	1.1	2.3	2.6
Monoclonal antibodies	Bevacizumab		95 and over	1.0	0.0	0.0	0.0	0.1	*	0.0	0.1	0.1
Monoclonal antibodies	Bevacizumab	Gender	Male	18.9	10.1	6.9	2.3	13.6	1.5	5.2	5.1	4.0
Monoclonal antibodies	Bevacizumab		Female	33.8	11.7	6.6	3.6	14.5	1.4	5.0	5.9	7.3
Monoclonal antibodies	Bevacizumab	Race	White	48.1	19.0	12.0	5.4	24.8	2.6	9.0	10.2	10.7
Monoclonal antibodies	Bevacizumab		Black	2.1	1.9	1.1	0.4	2.2	0.2	0.8	0.5	0.3
Monoclonal antibodies	Bevacizumab		Other	0.5	0.3	0.2	0.1	0.3	0.0	0.1	0.1	0.1
Monoclonal antibodies	Bevacizumab		Asian	0.7	0.3	0.2	0.1	0.3	0.0	0.1	0.1	0.1
Monoclonal antibodies	Bevacizumab		Hispanic	1.1	0.2	0.1	0.1	0.3	0.0	0.2	0.1	0.1
Monoclonal antibodies	Bevacizumab		American Indian/Alaska Native	0.3	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0
Other immunomodulators	Bortezomib	Total	All	0.9	27.8	3.9	97.9	21.1	1.4	8.5	21.2	11.0
Other immunomodulators	Bortezomib	Age	Under 45	0.1	0.1	*	0.5	0.1	*	*	0.1	0.1
Other immunomodulators	Bortezomib		45 to 54	0.1	0.7	0.1	2.5	0.4	0.0	0.1	0.5	0.1
Other immunomodulators	Bortezomib		55 to 64	0.1	2.1	0.3	7.3	1.2	0.1	0.6	1.3	0.6
Other immunomodulators	Bortezomib		65 to 74	0.3	12.7	1.9	42.6	8.8	0.7	3.8	9.3	4.7
Other immunomodulators	Bortezomib		75 to 84	0.2	10.1	1.4	37.1	8.9	0.5	3.3	8.3	4.5
Other immunomodulators	Bortezomib		85 to 94	0.1	1.9	0.2	7.7	1.7	0.1	0.6	1.7	0.9

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Bortezomib		95 and over	*	0.0	*	0.1	*	*	*	*	*
Other immunomodulators	Bortezomib	Gender	Male	0.5	15.0	2.3	54.3	12.7	0.9	5.2	12.6	5.6
Other immunomodulators	Bortezomib		Female	0.4	12.8	1.6	43.6	8.4	0.5	3.3	8.6	5.3
Other immunomodulators	Bortezomib	Race	White	0.7	22.7	3.3	80.4	17.4	1.2	7.0	18.2	10.1
Other immunomodulators	Bortezomib		Black	0.1	3.9	0.4	13.7	3.0	0.1	1.1	2.3	0.7
Other immunomodulators	Bortezomib		Other	*	0.4	0.1	1.2	0.2	*	0.1	0.2	0.1
Other immunomodulators	Bortezomib		Asian	*	0.2	0.0	0.8	0.1	*	0.1	0.1	*
Other immunomodulators	Bortezomib		Hispanic	*	0.5	0.1	1.5	0.3	*	0.1	0.3	0.1
Other immunomodulators	Bortezomib		American Indian/Alaska Native	*	0.1	*	0.3	0.1	*	*	0.1	*
Monoclonal antibodies	Cetuximab	Total	All	0.2	73.6	26.1	43.3	87.8	10.1	29.2	22.9	8.7
Monoclonal antibodies	Cetuximab	Age	Under 45	*	0.8	0.2	0.3	0.9	*	0.2	0.2	0.0
Monoclonal antibodies	Cetuximab		45 to 54	*	2.9	1.1	1.8	3.3	0.4	1.1	0.8	0.2
Monoclonal antibodies	Cetuximab		55 to 64	*	6.2	2.4	4.2	7.5	1.0	2.4	1.7	0.5
Monoclonal antibodies	Cetuximab		65 to 74	0.1	36.4	13.4	19.2	41.9	4.6	13.3	9.9	3.7
Monoclonal antibodies	Cetuximab		75 to 84	0.1	23.0	7.9	14.0	28.4	3.3	9.8	8.1	3.3
Monoclonal antibodies	Cetuximab		85 to 94	*	4.2	1.2	3.6	5.7	0.7	2.2	2.2	0.9
Monoclonal antibodies	Cetuximab		95 and over	*	0.1	*	0.2	0.2	*	0.1	0.1	0.0
Monoclonal antibodies	Cetuximab	Gender	Male	0.1	45.5	16.5	29.9	54.1	7.0	18.8	15.6	5.3
Monoclonal antibodies	Cetuximab		Female	0.1	28.0	9.7	13.4	33.6	3.1	10.4	7.3	3.4
Monoclonal antibodies	Cetuximab	Race	White	0.2	63.5	22.4	37.7	75.5	8.6	25.0	20.5	8.2
Monoclonal antibodies	Cetuximab		Black	*	7.0	2.7	4.0	8.7	1.1	2.9	1.7	0.3
Monoclonal antibodies	Cetuximab		Other	*	0.9	0.3	0.5	1.1	0.1	0.3	0.2	0.1
Monoclonal antibodies	Cetuximab		Asian	*	0.9	0.3	0.5	1.1	0.1	0.4	0.2	0.1
Monoclonal antibodies	Cetuximab		Hispanic	*	0.9	0.3	0.5	1.1	0.1	0.4	0.2	0.1
Monoclonal antibodies	Cetuximab		American Indian/Alaska Native	*	0.3	0.1	0.2	0.3	*	0.1	0.1	*
Other immunosuppressives	Cyclosporine	Total	All	69.8	1.9	2.3	4.0	5.5	0.7	5.7	12.5	13.0
Other immunosuppressives	Cyclosporine	Age	Under 45	15.0	0.2	0.2	0.4	0.4	0.1	0.4	0.9	1.2

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunosuppressives	Cyclosporine		45 to 54	15.0	0.2	0.4	0.5	0.6	0.1	0.9	1.7	1.9
Other immunosuppressives	Cyclosporine		55 to 64	16.4	0.3	0.6	0.7	1.0	0.2	1.4	2.4	2.5
Other immunosuppressives	Cyclosporine		65 to 74	17.5	0.8	0.9	1.6	2.3	0.3	2.2	5.1	5.1
Other immunosuppressives	Cyclosporine		75 to 84	4.8	0.3	0.2	0.7	1.1	0.1	0.7	2.2	2.0
Other immunosuppressives	Cyclosporine		85 to 94	0.6	0.0	0.0	0.1	0.1	*	0.1	0.2	0.2
Other immunosuppressives	Cyclosporine		95 and over	0.0	*	*	*	*	*	*	*	*
Other immunosuppressives	Cyclosporine	Gender	Male	40.2	1.1	1.5	2.4	3.4	0.4	3.4	8.0	7.0
Other immunosuppressives	Cyclosporine		Female	29.3	0.8	0.8	1.5	2.1	0.3	2.3	4.6	6.0
Other immunosuppressives	Cyclosporine	Race	White	46.8	1.6	1.9	3.3	4.4	0.5	4.2	11.2	11.5
Other immunosuppressives	Cyclosporine		Black	12.2	0.1	0.2	0.3	0.7	0.1	0.8	0.7	0.8
Other immunosuppressives	Cyclosporine		Other	2.2	*	0.1	0.1	0.1	*	0.2	0.1	0.2
Other immunosuppressives	Cyclosporine		Asian	2.8	0.0	0.1	0.1	0.1	*	0.2	0.2	0.2
Other immunosuppressives	Cyclosporine		Hispanic	4.9	0.1	0.1	0.2	0.2	*	0.3	0.2	0.3
Other immunosuppressives	Cyclosporine		American Indian/Alaska Native	0.6	*	*	*	*	*	0.0	0.0	0.1
Kinase inhibitors	Dasatinib	Total	All	*	26.6	90.5	50.1	12.2	*	6.6	11.0	9.3
Kinase inhibitors	Dasatinib	Age	Under 45	*	3.7	9.2	4.8	*	*	*	*	*
Kinase inhibitors	Dasatinib		45 to 54	*	3.5	10.2	6.2	1.1	*	*	1.0	1.1
Kinase inhibitors	Dasatinib		55 to 64	*	2.6	10.7	5.1	0.9	*	1.1	0.9	0.9
Kinase inhibitors	Dasatinib		65 to 74	*	8.3	29.9	15.4	4.4	*	2.5	4.0	3.0
Kinase inhibitors	Dasatinib		75 to 84	*	7.1	24.8	15.4	4.2	*	1.8	3.4	3.0
Kinase inhibitors	Dasatinib		85 to 94	*	1.4	5.5	3.2	1.0	*	*	1.0	*
Kinase inhibitors	Dasatinib	Gender	Male	*	11.0	35.2	19.8	5.9	*	2.2	4.9	3.1
Kinase inhibitors	Dasatinib		Female	*	15.7	55.2	30.2	6.2	*	4.4	6.1	6.2
Kinase inhibitors	Dasatinib	Race	White	*	20.9	70.3	40.5	10.6	*	5.4	9.4	7.8
Kinase inhibitors	Dasatinib		Black	*	3.4	12.7	6.1	*	*	0.9	*	*
Kinase inhibitors	Dasatinib		Other	*	*	1.6	*	*	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Kinase inhibitors	Dasatinib		Asian	*	*	1.7	*	*	*	*	*	*
Kinase inhibitors	Dasatinib		Hispanic	*	1.1	3.5	1.8	*	*	*	*	*
Biologic response modifiers	Denileukin	Total	All	47.8	12.5	3.3	36.2	11.4	1.0	5.2	9.6	11.2
Biologic response modifiers	Denileukin	Age	Under 45	4.6	0.9	*	2.8	0.2	*	*	0.4	0.3
Biologic response modifiers	Denileukin		45 to 54	7.3	1.1	*	4.4	0.5	*	0.3	0.5	0.8
Biologic response modifiers	Denileukin		55 to 64	5.5	0.8	*	3.0	0.7	*	0.4	0.6	0.7
Biologic response modifiers	Denileukin		65 to 74	14.1	4.9	1.6	12.6	4.7	0.4	2.0	4.0	4.8
Biologic response modifiers	Denileukin		75 to 84	12.0	3.7	1.0	10.1	4.3	0.3	1.9	3.2	3.8
Biologic response modifiers	Denileukin		85 to 94	3.9	1.1	0.2	3.1	1.0	*	0.5	0.8	0.7
Biologic response modifiers	Denileukin		95 and over	0.3	*	*	0.2	*	*	*	*	*
Biologic response modifiers	Denileukin	Gender	Male	23.1	6.0	1.8	17.5	5.4	0.5	2.4	4.6	3.3
Biologic response modifiers	Denileukin		Female	24.6	6.5	1.5	18.6	5.9	0.4	2.8	5.0	7.8
Biologic response modifiers	Denileukin	Race	White	20.1	6.5	2.4	18.5	6.9	0.6	3.0	6.4	6.9
Biologic response modifiers	Denileukin		Black	9.7	1.8	0.3	6.1	1.2	*	0.5	0.9	1.0
Biologic response modifiers	Denileukin		Other	0.6	*	*	0.5	*	*	*	*	*
Biologic response modifiers	Denileukin		Hispanic	17.2	4.1	0.6	11.0	3.1	0.3	1.6	2.2	3.1
Kinase inhibitors	Erlotinib	Total	All	0.3	63.4	97.5	15.1	36.0	21.4	13.8	14.3	8.9
Kinase inhibitors	Erlotinib	Age	Under 45	*	0.4	0.4	0.2	0.3	0.1	0.1	0.1	0.0
Kinase inhibitors	Erlotinib		45 to 54	*	1.9	2.4	0.6	1.1	0.5	0.3	0.3	0.1
Kinase inhibitors	Erlotinib		55 to 64	*	4.7	6.6	1.4	2.5	1.5	0.9	0.8	0.4
Kinase inhibitors	Erlotinib		65 to 74	0.1	29.4	42.9	7.3	16.0	9.0	6.4	5.9	3.7
Kinase inhibitors	Erlotinib		75 to 84	0.1	22.3	36.6	4.7	13.1	8.3	5.2	5.7	3.6
Kinase inhibitors	Erlotinib		85 to 94	*	4.6	8.4	1.0	3.1	2.2	1.0	1.4	1.1
Kinase inhibitors	Erlotinib		95 and over	*	0.1	0.2	*	0.1	0.0	*	*	*
Kinase inhibitors	Erlotinib	Gender	Male	0.1	27.3	41.1	6.8	15.7	9.0	6.4	6.3	2.8
Kinase inhibitors	Erlotinib		Female	0.2	36.0	56.3	8.3	20.3	12.4	7.3	7.9	6.1
Kinase inhibitors	Erlotinib	Race	White	0.2	51.4	79.1	12.3	29.4	16.8	11.3	12.0	7.9

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Kinase inhibitors	Erlotinib		Black	0.1	6.6	10.4	1.5	3.9	2.4	1.5	1.3	0.6
Kinase inhibitors	Erlotinib		Other	*	1.3	1.8	0.3	0.6	0.4	0.2	0.2	0.1
Kinase inhibitors	Erlotinib		Asian	0.1	2.8	4.2	0.7	1.3	1.3	0.5	0.5	0.2
Kinase inhibitors	Erlotinib		Hispanic	*	1.1	1.6	0.3	0.7	0.5	0.3	0.2	0.1
Kinase inhibitors	Erlotinib		American Indian/Alaska Native	*	0.2	0.3	0.1	0.1	0.1	*	*	*
Kinase inhibitors	Everolimus	Total	All	*	89.4	25.1	17.5	97.6	5.3	15.9	20.6	7.4
Kinase inhibitors	Everolimus	Age	45 to 54	*	5.6	*	*	5.6	*	*	*	*
Kinase inhibitors	Everolimus		55 to 64	*	9.8	4.2	*	11.6	*	*	*	*
Kinase inhibitors	Everolimus		65 to 74	*	52.1	15.9	9.3	55.6	3.2	8.7	12.2	3.7
Kinase inhibitors	Everolimus		75 to 84	*	17.7	*	3.7	19.8	*	3.2	4.8	*
Kinase inhibitors	Everolimus	Gender	Male	*	59.0	18.3	11.6	64.3	4.5	11.4	12.7	5.0
Kinase inhibitors	Everolimus		Female	*	30.2	6.9	5.8	33.1	*	4.5	7.9	*
Kinase inhibitors	Everolimus	Race	White	*	77.3	22.0	14.8	82.8	4.8	13.8	17.5	6.9
Kinase inhibitors	Everolimus		Black	*	5.0	*	*	7.1	*	*	*	*
Kinase inhibitors	Gefitinib	Total	All	*	34.6	93.0	8.3	18.9	13.5	*	9.9	8.3
Kinase inhibitors	Gefitinib	Age	45 to 54	*	*	4.5	*	*	*	*	*	*
Kinase inhibitors	Gefitinib		55 to 64	*	3.9	9.0	*	*	*	*	*	*
Kinase inhibitors	Gefitinib		65 to 74	*	12.2	37.2	*	8.3	6.7	*	4.5	*
Kinase inhibitors	Gefitinib		75 to 84	*	11.9	30.8	*	4.5	3.5	*	*	*
Kinase inhibitors	Gefitinib		85 to 94	*	*	10.6	*	*	*	*	*	*
Kinase inhibitors	Gefitinib	Gender	Male	*	9.9	26.0	4.2	7.7	3.5	*	4.2	*
Kinase inhibitors	Gefitinib		Female	*	24.7	67.0	4.2	11.2	9.9	*	5.8	6.1
Kinase inhibitors	Gefitinib	Race	White	*	26.6	74.4	6.4	14.7	9.3	*	7.7	7.1
Kinase inhibitors	Gefitinib		Black	*	*	5.8	*	*	*	*	*	*
Kinase inhibitors	Gefitinib		Asian	*	*	7.4	*	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab	Total	All	1.5	96.5	38.3	60.1	19.6	1.5	6.6	13.2	12.7
Monoclonal antibodies	Gemtuzumab	Age	Under 45	*	1.2	*	*	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab		45 to 54	*	1.7	0.9	1.6	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab		55 to 64	*	3.1	1.1	2.1	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab		65 to 74	*	43.9	18.0	28.6	7.5	*	2.4	6.2	6.1
Monoclonal antibodies	Gemtuzumab		75 to 84	*	40.8	15.7	23.7	9.4	*	3.1	5.6	5.2
Monoclonal antibodies	Gemtuzumab		85 to 94	*	5.6	1.9	3.2	1.3	*	*	*	0.9
Monoclonal antibodies	Gemtuzumab	Gender	Male	*	55.0	21.6	33.3	12.0	0.9	4.3	8.6	6.9
Monoclonal antibodies	Gemtuzumab		Female	*	41.5	16.7	26.8	7.6	*	2.3	4.6	5.7
Monoclonal antibodies	Gemtuzumab	Race	White	1.1	87.8	34.5	54.2	17.5	1.3	6.0	12.2	12.1
Monoclonal antibodies	Gemtuzumab		Black	*	4.4	2.0	3.2	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab		Other	*	1.5	*	*	*	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Monoclonal antibodies	Gemtuzumab		Asian	*	1.1	*	*	*	*	*	*	*
Monoclonal antibodies	Gemtuzumab		Hispanic	*	1.5	*	1.1	*	*	*	*	*
Monoclonal antibodies	Ibritumomab	Total	All	15.1	11.2	6.8	70.9	20.7	1.5	10.8	20.5	16.9
Monoclonal antibodies	Ibritumomab	Age	Under 45	1.4	*	*	*	*	*	*	*	*
Monoclonal antibodies	Ibritumomab		45 to 54	1.8	*	*	1.9	*	*	0.6	0.6	*
Monoclonal antibodies	Ibritumomab		55 to 64	2.3	0.7	*	4.5	0.8	*	0.6	0.8	0.9
Monoclonal antibodies	Ibritumomab		65 to 74	4.9	5.5	3.1	33.5	9.5	0.7	5.3	9.2	7.8
Monoclonal antibodies	Ibritumomab		75 to 84	3.8	3.9	2.8	25.4	8.2	0.6	3.4	8.1	6.5
Monoclonal antibodies	Ibritumomab		85 to 94	0.7	0.8	*	5.3	1.7	*	0.9	1.8	1.1
Monoclonal antibodies	Ibritumomab	Gender	Male	5.1	5.8	3.5	35.5	9.5	0.8	5.6	10.5	6.6
Monoclonal antibodies	Ibritumomab		Female	9.9	5.4	3.3	35.4	11.2	0.6	5.1	10.1	10.3
Monoclonal antibodies	Ibritumomab	Race	White	12.9	10.2	5.9	67.0	18.9	1.4	9.9	19.5	15.9
Monoclonal antibodies	Ibritumomab		Black	1.8	0.5	*	2.0	1.1	*	0.7	0.6	*
Monoclonal antibodies	Ibritumomab		Other	*	*	*	0.7	*	*	*	*	*
Monoclonal antibodies	Ibritumomab		Hispanic	*	*	*	0.6	*	*	*	*	*
Kinase inhibitors	Imatinib	Total	All	5.1	22.6	76.7	42.6	24.4	1.1	20.0	23.3	10.4
Kinase inhibitors	Imatinib	Age	Under 45	0.4	1.2	3.5	2.1	0.7	*	0.4	0.7	0.3
Kinase inhibitors	Imatinib		45 to 54	0.6	1.7	5.6	2.8	1.1	*	0.9	1.2	0.6
Kinase inhibitors	Imatinib		55 to 64	0.6	2.0	7.3	3.9	1.7	*	1.4	1.5	0.7
Kinase inhibitors	Imatinib		65 to 74	1.6	8.6	27.9	15.3	9.5	0.5	7.9	9.3	4.2
Kinase inhibitors	Imatinib		75 to 84	1.5	7.2	24.5	13.8	8.6	0.4	7.1	7.8	3.6
Kinase inhibitors	Imatinib		85 to 94	0.4	1.9	7.5	4.5	2.7	0.1	2.1	2.6	0.9
Kinase inhibitors	Imatinib		95 and over	*	*	0.4	0.2	0.2	*	*	*	*
Kinase inhibitors	Imatinib	Gender	Male	2.4	10.6	35.3	19.2	12.3	0.4	9.3	10.8	4.0
Kinase inhibitors	Imatinib		Female	2.7	12.0	41.3	23.3	12.1	0.7	10.6	12.4	6.3
Kinase inhibitors	Imatinib	Race	White	3.8	17.3	60.3	33.2	19.0	0.9	14.6	17.8	9.3
Kinase inhibitors	Imatinib		Black	0.5	3.4	10.9	6.0	3.6	0.2	3.4	3.5	0.7
Kinase inhibitors	Imatinib		Other	*	0.3	1.0	0.6	0.3	*	0.4	0.4	*
Kinase inhibitors	Imatinib		Asian	*	0.7	2.0	1.1	0.8	*	0.9	0.9	*
Kinase inhibitors	Imatinib		Hispanic	0.6	0.8	2.1	1.5	0.7	*	0.6	0.6	0.2
Kinase inhibitors	Imatinib		American Indian/Alaska Native	*	0.1	0.4	0.2	*	*	*	0.1	*
Other immunomodulators	Interferon alfa-2b	Total	All	4.3	21.0	7.0	11.8	88.7	1.6	48.1	24.5	19.2
Other immunomodulators	Interferon alfa-2b	Age	Under 45	0.3	0.4	0.1	0.3	0.5	*	0.1	0.3	0.2
Other immunomodulators	Interferon alfa-2b		45 to 54	0.7	0.9	0.3	0.5	1.3	*	0.4	0.6	0.5

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Interferon alfa-2b		55 to 64	0.6	1.5	0.6	0.9	3.3	0.1	1.4	1.0	0.9
Other immunomodulators	Interferon alfa-2b		65 to 74	1.4	11.3	3.4	5.7	36.8	0.8	18.7	10.9	9.2
Other immunomodulators	Interferon alfa-2b		75 to 84	1.0	6.0	2.3	3.7	36.4	0.6	21.4	9.2	6.8
Other immunomodulators	Interferon alfa-2b		85 to 94	0.2	1.0	0.4	0.7	10.2	0.1	6.0	2.5	1.6
Other immunomodulators	Interferon alfa-2b		95 and over	*	*	*	*	0.3	*	0.2	*	*
Other immunomodulators	Interferon alfa-2b	Gender	Male	2.5	13.8	4.4	7.5	66.8	1.1	37.4	18.0	13.0
Other immunomodulators	Interferon alfa-2b		Female	1.9	7.2	2.6	4.2	21.9	0.5	10.8	6.6	6.2
Other immunomodulators	Interferon alfa-2b	Race	White	3.4	19.4	6.3	10.6	83.9	1.5	45.6	23.5	18.7
Other immunomodulators	Interferon alfa-2b		Black	0.6	0.9	0.5	0.7	2.9	0.1	1.7	0.6	0.3
Other immunomodulators	Interferon alfa-2b		Other	0.1	0.2	*	0.1	0.6	*	0.3	0.2	0.1
Other immunomodulators	Interferon alfa-2b		Asian	*	0.1	0.1	*	0.3	*	0.2	*	*
Other immunomodulators	Interferon alfa-2b		Hispanic	0.2	0.2	0.1	0.2	0.8	*	0.3	0.3	0.1
Other immunomodulators	Interferon alfa-2b		American Indian/Alaska Native	*	0.1	*	*	0.2	*	*	*	*
Other immunomodulators	Interferon gamma-1b	Total	All	67.7	6.0	4.6	6.0	12.4	2.0	5.7	10.8	10.7
Other immunomodulators	Interferon gamma-1b	Age	Under 45	5.6	*	*	*	*	*	*	*	*
Other immunomodulators	Interferon gamma-1b		45 to 54	5.1	*	*	*	*	*	*	*	*
Other immunomodulators	Interferon gamma-1b		55 to 64	9.0	*	*	*	*	*	*	*	*
Other immunomodulators	Interferon gamma-1b		65 to 74	25.7	2.2	2.2	2.6	4.3	*	*	4.2	4.2
Other immunomodulators	Interferon gamma-1b		75 to 84	17.7	2.6	1.9	2.3	4.8	*	2.9	4.0	4.0
Other immunomodulators	Interferon gamma-1b		85 to 94	3.9	*	*	*	1.9	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Interferon gamma-1b	Gender	Male	29.1	2.5	2.3	2.3	6.2	*	3.3	5.6	3.9
Other immunomodulators	Interferon gamma-1b		Female	38.1	3.6	2.3	3.7	6.2	*	2.5	5.3	6.8
Other immunomodulators	Interferon gamma-1b	Race	White	47.8	4.3	3.7	5.0	9.6	*	4.3	9.1	8.8
Other immunomodulators	Interferon gamma-1b		Black	9.9	*	*	*	*	*	*	*	*
Other immunomodulators	Interferon gamma-1b		Asian	3.7	*	*	*	*	*	*	*	*
Other immunomodulators	Interferon gamma-1b		Hispanic	3.7	*	*	*	*	*	*	*	*
Kinase inhibitors	Lapatinib	Total	All	*	87.9	12.1	13.4	99.5	1.8	3.8	24.5	16.8
Kinase inhibitors	Lapatinib	Age	Under 45	*	7.6	0.9	1.6	8.1	*	*	1.8	1.6
Kinase inhibitors	Lapatinib		45 to 54	*	13.6	1.8	2.2	14.8	*	*	3.6	2.4
Kinase inhibitors	Lapatinib		55 to 64	*	14.9	1.8	2.4	16.5	*	*	4.2	3.0
Kinase inhibitors	Lapatinib		65 to 74	*	35.8	5.5	5.3	40.8	*	1.8	9.9	6.2
Kinase inhibitors	Lapatinib		75 to 84	*	13.4	1.7	1.7	16.0	*	0.8	3.7	2.7
Kinase inhibitors	Lapatinib		85 to 94	*	2.4	*	*	3.0	*	*	1.3	0.8
Kinase inhibitors	Lapatinib	Gender	Male	*	1.2	*	*	1.2	*	*	*	*
Kinase inhibitors	Lapatinib		Female	*	86.6	11.7	13.2	98.2	1.7	3.7	24.1	16.6
Kinase inhibitors	Lapatinib	Race	White	*	69.4	9.5	10.7	77.5	1.2	2.7	19.0	12.3
Kinase inhibitors	Lapatinib		Black	*	12.3	1.9	1.8	14.7	*	0.7	4.0	3.4
Kinase inhibitors	Lapatinib		Other	*	0.9	*	*	1.2	*	*	*	*
Kinase inhibitors	Lapatinib		Asian	*	2.1	*	*	2.4	*	*	*	*
Kinase inhibitors	Lapatinib		Hispanic	*	2.8	*	*	3.2	*	*	0.7	0.6
Other immunomodulators	Lenalidomide	Total	All	12.9	23.6	4.1	78.0	17.9	1.1	7.1	17.7	10.4
Other immunomodulators	Lenalidomide	Age	Under 45	*	0.2	*	0.9	0.1	*	*	0.1	0.1
Other immunomodulators	Lenalidomide		45 to 54	0.2	0.8	0.1	3.0	0.3	*	0.1	0.6	0.2
Other immunomodulators	Lenalidomide		55 to 64	0.4	2.0	0.3	7.1	1.2	0.1	0.5	1.4	0.7
Other immunomodulators	Lenalidomide		65 to 74	3.5	10.8	1.8	35.3	7.3	0.5	3.2	8.0	4.2
Other immunomodulators	Lenalidomide		75 to 84	5.8	8.0	1.5	26.0	7.1	0.4	2.6	6.2	4.2
Other immunomodulators	Lenalidomide		85 to 94	2.8	1.6	0.3	5.6	1.9	*	0.6	1.5	1.0

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Lenalidomide		95 and over	0.1	*	*	0.1	*	*	*	*	*
Other immunomodulators	Lenalidomide	Gender	Male	5.3	11.6	2.0	37.6	9.8	0.6	3.8	9.4	4.5
Other immunomodulators	Lenalidomide		Female	7.6	11.9	2.1	40.3	8.1	0.6	3.3	8.4	5.8
Other immunomodulators	Lenalidomide	Race	White	11.5	19.2	3.5	61.5	14.9	0.9	5.9	15.0	9.4
Other immunomodulators	Lenalidomide		Black	0.6	3.0	0.4	12.2	2.2	0.1	0.8	1.9	0.7
Other immunomodulators	Lenalidomide		Other	0.1	0.3	0.1	1.1	0.2	*	0.1	0.2	*
Other immunomodulators	Lenalidomide		Asian	0.3	0.3	0.1	1.1	0.2	*	0.2	0.3	*
Other immunomodulators	Lenalidomide		Hispanic	0.3	0.6	0.1	1.8	0.3	*	0.2	0.4	0.1
Other immunomodulators	Lenalidomide		American Indian/Alaska Native	*	*	*	0.3	*	*	*	*	*
Kinase inhibitors	Nilotinib	Total	All	*	28.4	93.8	49.6	15.1	*	6.4	13.1	9.1
Kinase inhibitors	Nilotinib	Age	Under 45	*	3.7	12.2	6.8	*	*	*	*	*
Kinase inhibitors	Nilotinib		45 to 54	*	4.4	12.7	5.6	*	*	*	*	*
Kinase inhibitors	Nilotinib		55 to 64	*	2.7	10.2	4.4	*	*	*	*	*
Kinase inhibitors	Nilotinib		65 to 74	*	10.2	33.4	18.9	7.0	*	2.9	5.4	3.9
Kinase inhibitors	Nilotinib		75 to 84	*	6.4	19.9	9.7	4.1	*	*	3.3	2.9
Kinase inhibitors	Nilotinib		85 to 94	*	*	5.0	3.9	*	*	*	*	*
Kinase inhibitors	Nilotinib	Gender	Male	*	12.9	35.9	19.9	6.0	*	2.3	6.4	2.9
Kinase inhibitors	Nilotinib		Female	*	15.4	57.9	29.7	9.1	*	4.1	6.8	6.2
Kinase inhibitors	Nilotinib	Race	White	*	21.8	71.2	39.4	12.0	*	5.8	10.4	7.7
Kinase inhibitors	Nilotinib		Black	*	3.7	11.8	5.6	*	*	*	*	*
Kinase inhibitors	Nilotinib		Other	*	*	2.3	*	*	*	*	*	*
Kinase inhibitors	Nilotinib		Asian	*	*	3.5	*	*	*	*	*	*
Kinase inhibitors	Nilotinib		Hispanic	*	*	4.6	2.1	*	*	*	*	*
Miscellaneous biologic nonblood products	Octreotide acetate	Total	All	20.1	46.6	34.9	13.4	61.1	3.7	30.0	19.9	9.5
Miscellaneous biologic nonblood products	Octreotide acetate	Age	Under 45	2.4	0.5	0.4	0.6	0.8	0.1	0.5	0.4	0.2
Miscellaneous biologic nonblood products	Octreotide acetate		45 to 54	3.6	1.5	1.2	0.8	2.1	0.2	1.1	0.9	0.5
Miscellaneous biologic nonblood products	Octreotide acetate		55 to 64	2.9	3.3	2.7	1.2	4.5	0.3	2.0	1.7	0.7

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Miscellaneous biologic nonblood products	Octreotide acetate		65 to 74	5.0	22.3	16.1	5.9	27.8	1.7	13.6	8.6	4.1
Miscellaneous biologic nonblood products	Octreotide acetate		75 to 84	4.2	16.2	12.4	4.1	21.7	1.3	10.8	6.9	3.3
Miscellaneous biologic nonblood products	Octreotide acetate		85 to 94	1.7	2.7	2.1	0.8	4.1	0.3	1.9	1.4	0.7
Miscellaneous biologic nonblood products	Octreotide acetate		95 and over	0.2	*	*	*	0.1	*	*	*	*
Miscellaneous biologic nonblood products	Octreotide acetate	Gender	Male	9.5	22.5	17.3	5.8	28.7	1.6	14.9	9.0	3.4
Miscellaneous biologic nonblood products	Octreotide acetate		Female	10.5	24.1	17.6	7.6	32.4	2.0	15.1	10.9	6.2
Miscellaneous biologic nonblood products	Octreotide acetate	Race	White	13.6	41.7	31.1	11.2	54.5	3.2	26.6	17.7	8.5
Miscellaneous biologic nonblood products	Octreotide acetate		Black	3.8	3.5	2.7	1.3	4.8	0.3	2.3	1.6	0.6
Miscellaneous biologic nonblood products	Octreotide acetate		Other	0.3	0.4	0.3	0.1	0.5	*	0.3	0.1	0.1
Miscellaneous biologic nonblood products	Octreotide acetate		Asian	0.2	0.4	0.3	0.1	0.4	0.1	0.2	0.1	0.1
Miscellaneous biologic nonblood products	Octreotide acetate		Hispanic	2.0	0.5	0.4	0.6	0.8	0.1	0.5	0.3	0.3
Miscellaneous biologic nonblood products	Octreotide acetate		American Indian/Alaska Native	0.2	0.1	0.1	0.1	0.2	*	0.1	0.1	*
Monoclonal antibodies	Panitumumab	Total	All	0.3	84.9	24.0	6.3	98.7	2.5	17.2	8.7	4.8
Monoclonal antibodies	Panitumumab	Age	Under 45	*	1.4	0.5	*	1.5	*	*	*	*
Monoclonal antibodies	Panitumumab		45 to 54	*	4.0	1.2	*	4.6	*	0.9	0.3	*
Monoclonal antibodies	Panitumumab		55 to 64	*	8.7	2.4	0.7	9.9	*	1.5	0.7	0.3
Monoclonal antibodies	Panitumumab		65 to 74	*	43.8	11.8	3.3	50.2	1.4	8.5	4.4	2.2
Monoclonal antibodies	Panitumumab		75 to 84	*	22.6	6.7	1.7	27.0	0.6	4.8	2.6	1.7
Monoclonal antibodies	Panitumumab		85 to 94	*	4.4	1.3	0.3	5.3	*	1.2	0.5	0.4
Monoclonal antibodies	Panitumumab	Gender	Male	*	48.2	13.9	3.4	55.4	1.2	9.7	4.7	2.3
Monoclonal antibodies	Panitumumab		Female	*	36.7	10.1	2.9	43.3	1.2	7.4	4.0	2.4
Monoclonal antibodies	Panitumumab	Race	White	*	71.2	20.2	5.4	82.9	2.1	14.2	7.4	4.3
Monoclonal antibodies	Panitumumab		Black	*	9.6	2.7	0.6	11.0	*	2.1	0.9	0.3
Monoclonal antibodies	Panitumumab		Other	*	1.3	0.4	*	1.5	*	0.3	*	*
Monoclonal antibodies	Panitumumab		Asian	*	1.4	0.5	*	1.5	*	0.3	*	*
Monoclonal antibodies	Panitumumab		Hispanic	*	1.0	0.3	*	1.2	*	*	*	*
Monoclonal antibodies	Panitumumab		American Indian/Alaska	*	0.4	*	*	0.5	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
			Native									
Kinase inhibitors	Pazopanib	Total	All	*	96.7	*	*	100.0	*	*	36.7	*
Kinase inhibitors	Pazopanib	Age	65 to 74	*	66.7	*	*	70.0	*	*	*	*
Kinase inhibitors	Pazopanib	Gender	Male	*	66.7	*	*	66.7	*	*	*	*
Kinase inhibitors	Pazopanib	Race	White	*	83.3	*	*	86.7	*	*	*	*
Miscellaneous biologic nonblood products	Pegaspargase	Total	All	15.4	68.4	21.3	52.9	25.0	*	*	18.4	14.0
Miscellaneous biologic nonblood products	Pegaspargase	Age	Under 45	*	12.5	*	10.3	*	*	*	*	*
Miscellaneous biologic nonblood products	Pegaspargase		65 to 74	*	27.2	10.3	17.7	12.5	*	*	11.0	8.1
Miscellaneous biologic nonblood products	Pegaspargase		75 to 84	*	16.2	*	16.9	8.1	*	*	*	*
Miscellaneous biologic nonblood products	Pegaspargase	Gender	Male	*	36.8	12.5	25.0	13.2	*	*	*	*
Miscellaneous biologic nonblood products	Pegaspargase		Female	9.6	31.6	8.8	27.9	11.8	*	*	12.5	8.1
Miscellaneous biologic nonblood products	Pegaspargase	Race	White	*	50.7	16.9	39.7	19.1	*	*	13.2	11.0
Miscellaneous biologic nonblood products	Pegaspargase		Black	*	10.3	*	*	*	*	*	*	*
Other immunomodulators	Peginterferon alfa-2a	Total	All	77.7	0.4	2.1	1.6	2.9	0.3	9.7	4.6	6.4
Other immunomodulators	Peginterferon alfa-2a	Age	Under 45	16.1	*	0.2	0.3	0.3	*	0.8	0.7	1.0
Other immunomodulators	Peginterferon alfa-2a		45 to 54	35.4	0.1	0.7	0.7	0.9	0.1	4.3	2.1	2.9
Other immunomodulators	Peginterferon alfa-2a		55 to 64	17.9	0.1	0.6	0.3	0.8	*	2.8	1.1	1.5
Other immunomodulators	Peginterferon alfa-2a		65 to 74	7.4	0.1	0.5	0.2	0.7	*	1.6	0.7	0.9
Other immunomodulators	Peginterferon alfa-2a		75 to 84	0.7	*	0.1	*	0.1	*	0.3	0.1	0.1
Other immunomodulators	Peginterferon alfa-2a		85 to 94	*	*	*	*	*	*	*	*	*
Other immunomodulators	Peginterferon alfa-2a		95 and over	*	*	*	*	*	*	*	*	*
Other immunomodulators	Peginterferon alfa-2a	Gender	Male	47.3	0.2	1.4	1.0	1.6	0.2	5.4	2.2	2.5
Other immunomodulators	Peginterferon alfa-2a		Female	30.3	0.2	0.7	0.6	1.3	0.1	4.3	2.4	3.9

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Other immunomodulators	Peginterferon alfa-2a	Race	White	52.9	0.3	1.4	1.1	1.9	0.2	6.5	3.2	4.8
Other immunomodulators	Peginterferon alfa-2a		Black	16.7	*	0.3	0.3	0.8	*	2.2	1.0	1.1
Other immunomodulators	Peginterferon alfa-2a		Other	1.0	*	*	*	*	*	0.2	*	*
Other immunomodulators	Peginterferon alfa-2a		Asian	2.1	*	0.1	*	0.1	*	0.4	0.1	0.1
Other immunomodulators	Peginterferon alfa-2a		Hispanic	4.2	*	0.1	0.1	0.1	*	0.4	0.2	0.3
Other immunomodulators	Peginterferon alfa-2a		American Indian/Alaska Native	0.7	*	*	*	*	*	0.1	*	*
Other immunomodulators	Peginterferon alfa-2b	Total	All	76.7	0.8	1.8	1.7	3.2	0.4	9.9	4.7	7.1
Other immunomodulators	Peginterferon alfa-2b	Age	Under 45	16.0	*	*	0.3	0.3	*	0.7	0.8	1.2
Other immunomodulators	Peginterferon alfa-2b		45 to 54	35.5	0.2	0.4	0.6	1.0	*	4.1	1.9	2.9
Other immunomodulators	Peginterferon alfa-2b		55 to 64	16.6	*	0.7	0.3	0.7	*	3.0	1.1	1.6
Other immunomodulators	Peginterferon alfa-2b		65 to 74	7.7	0.4	0.5	0.3	1.0	*	1.9	0.9	1.2
Other immunomodulators	Peginterferon alfa-2b		75 to 84	0.9	*	*	*	*	*	*	*	*
Other immunomodulators	Peginterferon alfa-2b	Gender	Male	44.9	0.4	1.1	1.0	1.8	0.3	5.7	2.4	2.5
Other immunomodulators	Peginterferon alfa-2b		Female	31.7	0.4	0.7	0.7	1.3	*	4.2	2.3	4.6
Other immunomodulators	Peginterferon alfa-2b	Race	White	54.3	0.6	1.2	1.2	2.2	0.3	6.8	3.4	5.6
Other immunomodulators	Peginterferon alfa-2b		Black	14.9	*	0.3	0.3	0.7	*	2.2	0.9	1.2
Other immunomodulators	Peginterferon alfa-2b		Other	1.0	*	*	*	*	*	*	*	*
Other immunomodulators	Peginterferon alfa-2b		Asian	1.9	*	*	*	*	*	0.4	*	*
Other immunomodulators	Peginterferon alfa-2b		Hispanic	3.6	*	*	*	0.2	*	0.3	0.2	0.2
Other immunomodulators	Peginterferon alfa-2b		American Indian/Alaska Native	0.9	*	*	*	*	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Monoclonal antibodies	Rituximab	Total	All	11.1	11.9	8.0	84.0	20.6	2.7	13.7	23.2	16.2
Monoclonal antibodies	Rituximab	Age	Under 45	1.2	0.1	0.1	0.5	0.1	0.0	0.1	0.2	0.1
Monoclonal antibodies	Rituximab		45 to 54	1.3	0.2	0.1	1.4	0.3	0.0	0.2	0.4	0.3
Monoclonal antibodies	Rituximab		55 to 64	1.7	0.5	0.4	3.6	0.7	0.1	0.6	0.9	0.7
Monoclonal antibodies	Rituximab		65 to 74	3.7	4.6	3.0	32.2	7.3	1.0	5.4	8.5	6.1
Monoclonal antibodies	Rituximab		75 to 84	2.5	4.9	3.4	34.8	9.2	1.2	5.7	9.9	6.8
Monoclonal antibodies	Rituximab		85 to 94	0.7	1.5	1.0	11.0	3.0	0.3	1.6	3.3	2.2
Monoclonal antibodies	Rituximab		95 and over	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.1	0.1
Monoclonal antibodies	Rituximab	Gender	Male	3.4	6.1	4.3	42.9	11.3	1.4	7.3	12.5	7.1
Monoclonal antibodies	Rituximab		Female	7.7	5.8	3.7	41.0	9.4	1.3	6.3	10.7	9.1
Monoclonal antibodies	Rituximab	Race	White	8.9	10.9	7.3	77.7	19.1	2.5	12.6	21.8	15.5
Monoclonal antibodies	Rituximab		Black	1.2	0.6	0.4	3.7	0.9	0.1	0.6	0.7	0.4
Monoclonal antibodies	Rituximab		Other	0.2	0.1	0.1	0.7	0.2	0.0	0.1	0.2	0.1
Monoclonal antibodies	Rituximab		Asian	0.1	0.1	0.1	0.6	0.2	0.0	0.1	0.2	0.1
Monoclonal antibodies	Rituximab		Hispanic	0.5	0.2	0.1	1.0	0.3	0.0	0.2	0.2	0.1
Monoclonal antibodies	Rituximab		American Indian/Alaska Native	0.1	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0
Kinase inhibitors	Sorafenib	Total	All	0.4	62.8	63.2	13.9	63.3	4.9	31.5	20.2	8.4
Kinase inhibitors	Sorafenib	Age	Under 45	*	1.1	0.7	0.5	1.1	*	0.4	0.4	*
Kinase inhibitors	Sorafenib		45 to 54	*	3.8	5.1	1.0	3.4	0.2	2.2	1.2	0.4
Kinase inhibitors	Sorafenib		55 to 64	*	7.8	9.8	1.9	6.8	0.5	4.5	2.3	0.9
Kinase inhibitors	Sorafenib		65 to 74	*	30.4	27.2	6.6	30.7	2.5	14.0	9.5	3.8
Kinase inhibitors	Sorafenib		75 to 84	*	17.2	17.4	3.4	18.4	1.4	8.9	6.1	2.8
Kinase inhibitors	Sorafenib		85 to 94	*	2.5	2.9	0.5	2.8	*	1.5	0.8	0.5
Kinase inhibitors	Sorafenib	Gender	Male	0.2	40.0	43.4	8.5	39.6	2.9	21.4	12.9	4.5
Kinase inhibitors	Sorafenib		Female	*	22.7	19.7	5.4	23.6	2.0	10.2	7.3	3.9
Kinase inhibitors	Sorafenib	Race	White	0.2	48.6	42.5	10.8	49.8	3.9	21.7	16.1	7.2
Kinase inhibitors	Sorafenib		Black	*	6.2	8.0	1.5	6.4	0.4	4.1	1.9	0.5
Kinase inhibitors	Sorafenib		Other	*	1.7	2.4	0.3	1.4	*	1.1	0.2	*
Kinase inhibitors	Sorafenib		Asian	*	3.0	6.2	0.6	2.4	0.3	2.7	0.9	0.2
Kinase inhibitors	Sorafenib		Hispanic	*	2.4	3.3	0.5	2.4	*	1.7	0.8	0.2
Kinase inhibitors	Sorafenib		American Indian/Alaska Native	*	0.8	0.8	*	0.8	*	0.3	0.3	*
Kinase inhibitors	Sunitinib	Total	All	57.9	33.9	17.1	11.9	37.0	2.7	11.0	14.0	4.1
Kinase inhibitors	Sunitinib	Age	Under 45	0.8	0.8	0.4	0.4	0.8	*	*	0.4	*
Kinase inhibitors	Sunitinib		45 to 54	2.5	2.2	1.3	1.0	2.2	*	0.6	1.0	*
Kinase inhibitors	Sunitinib		55 to 64	5.3	3.9	2.0	0.9	4.3	0.2	1.2	1.4	0.5

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Kinase inhibitors	Sunitinib		65 to 74	27.4	17.3	8.3	5.5	19.1	1.4	5.5	6.5	2.1
Kinase inhibitors	Sunitinib		75 to 84	18.3	9.0	4.5	3.6	9.6	0.7	3.1	4.0	1.2
Kinase inhibitors	Sunitinib		85 to 94	3.4	0.7	0.6	0.5	0.9	*	0.4	0.5	*
Kinase inhibitors	Sunitinib	Gender	Male	33.4	19.8	9.6	6.3	21.8	1.7	6.3	7.9	2.1
Kinase inhibitors	Sunitinib		Female	24.3	14.1	7.4	5.6	15.1	1.0	4.8	6.0	2.0
Kinase inhibitors	Sunitinib	Race	White	47.9	28.0	13.4	9.7	30.5	2.3	8.9	11.5	3.8
Kinase inhibitors	Sunitinib		Black	5.3	3.3	2.3	1.4	3.5	*	1.3	1.6	*
Kinase inhibitors	Sunitinib		Other	1.2	0.6	0.3	*	0.7	*	0.2	0.2	*
Kinase inhibitors	Sunitinib		Asian	1.3	0.8	0.6	0.4	0.9	*	0.4	*	*
Kinase inhibitors	Sunitinib		Hispanic	1.7	0.9	0.4	0.3	1.1	*	0.3	0.3	*
Kinase inhibitors	Sunitinib		American Indian/Alaska Native	0.5	0.2	*	*	0.3	*	*	*	*
Kinase inhibitors	Temsirolimus	Total	All	64.8	30.2	9.3	6.9	33.6	2.1	5.3	6.9	2.8
Kinase inhibitors	Temsirolimus	Age	Under 45	0.5	0.4	*	*	0.5	*	*	*	*
Kinase inhibitors	Temsirolimus		45 to 54	2.3	1.6	*	*	1.7	*	*	*	*
Kinase inhibitors	Temsirolimus		55 to 64	4.8	3.6	0.9	0.7	3.7	*	0.5	0.6	*
Kinase inhibitors	Temsirolimus		65 to 74	33.1	17.1	5.2	4.1	18.8	1.3	3.0	4.1	1.5
Kinase inhibitors	Temsirolimus		75 to 84	20.7	6.8	2.5	1.5	8.0	*	1.2	1.6	0.8
Kinase inhibitors	Temsirolimus		85 to 94	3.4	0.6	*	*	0.9	*	*	*	*
Kinase inhibitors	Temsirolimus	Gender	Male	43.2	19.8	5.9	4.0	21.9	1.4	3.4	4.9	1.7
Kinase inhibitors	Temsirolimus		Female	21.5	10.4	3.4	2.9	11.7	0.6	1.9	2.0	1.1
Kinase inhibitors	Temsirolimus	Race	White	57.1	25.6	7.8	6.0	28.7	1.7	4.6	6.1	2.7
Kinase inhibitors	Temsirolimus		Black	4.9	2.6	0.8	0.4	2.7	*	0.5	0.6	*
Kinase inhibitors	Temsirolimus		Other	0.8	0.5	*	*	0.5	*	*	*	*
Kinase inhibitors	Temsirolimus		Asian	0.6	*	*	*	0.5	*	*	*	*
Kinase inhibitors	Temsirolimus		Hispanic	0.8	0.9	*	*	1.0	*	*	*	*
Kinase inhibitors	Tositumomab	Total	All	55.7	5.7	2.2	43.7	8.1	1.0	4.2	11.3	7.3
Kinase inhibitors	Tositumomab	Age	Under 45	1.1	*	*	*	*	*	*	*	*
Kinase inhibitors	Tositumomab		45 to 54	2.5	*	*	1.6	*	*	*	*	*
Kinase inhibitors	Tositumomab		55 to 64	2.9	*	*	2.6	*	*	*	*	*
Kinase inhibitors	Tositumomab		65 to 74	27.1	2.7	1.1	21.7	4.3	*	2.4	6.0	4.3
Kinase inhibitors	Tositumomab		75 to 84	17.6	2.3	*	15.4	3.3	*	1.3	3.6	2.1
Kinase inhibitors	Tositumomab		85 to 94	4.4	*	*	2.1	*	*	*	*	*
Kinase inhibitors	Tositumomab	Gender	Male	20.3	2.6	1.5	21.2	4.5	*	2.3	6.3	3.9
Kinase inhibitors	Tositumomab		Female	35.4	3.2	*	22.5	3.6	*	1.9	5.0	3.4
Kinase inhibitors	Tositumomab	Race	White	47.0	5.4	2.2	41.2	7.6	0.9	4.0	10.9	7.3
Kinase inhibitors	Tositumomab		Black	4.2	*	*	1.3	*	*	*	*	*
Kinase inhibitors	Tositumomab		Hispanic	2.7	*	*	*	*	*	*	*	*

Class	Active Ingredient	Breakdown	Category	Percentage of Beneficiaries With Condition Category in Period of Continuous Enrollment Prior to First Relevant Claim								
				No Cancer Diagnosis	CC 7	CC 8	CC 9	CC 10	CC 11	CC 12	CC 13	CC 14
Kinase inhibitors	Trastuzumab	Total	All	88.3	8.6	1.7	1.9	11.0	0.4	0.9	3.5	4.4
Kinase inhibitors	Trastuzumab	Age	Under 45	1.5	0.3	0.0	0.1	0.4	*	*	0.1	0.1
Kinase inhibitors	Trastuzumab		45 to 54	4.4	0.8	0.1	0.1	0.9	*	0.1	0.2	0.3
Kinase inhibitors	Trastuzumab		55 to 64	8.2	1.1	0.2	0.2	1.3	0.1	0.1	0.4	0.4
Kinase inhibitors	Trastuzumab		65 to 74	45.0	4.1	0.9	0.9	5.2	0.2	0.5	1.7	2.3
Kinase inhibitors	Trastuzumab		75 to 84	24.3	2.1	0.4	0.5	2.8	0.1	0.3	0.9	1.2
Kinase inhibitors	Trastuzumab		85 to 94	4.8	0.3	0.1	0.1	0.4	*	*	0.2	0.2
Kinase inhibitors	Trastuzumab		95 and over	0.2	*	*	*	*	*	*	*	*
Kinase inhibitors	Trastuzumab	Gender	Male	1.7	0.5	0.3	0.4	0.6	0.1	0.2	0.2	0.2
Kinase inhibitors	Trastuzumab		Female	86.6	8.1	1.4	1.5	10.4	0.3	0.7	3.3	4.2
Kinase inhibitors	Trastuzumab	Race	White	75.4	7.3	1.4	1.7	9.3	0.3	0.8	3.0	3.7
Kinase inhibitors	Trastuzumab		Black	9.4	1.0	0.2	0.2	1.2	0.1	0.1	0.4	0.5
Kinase inhibitors	Trastuzumab		Other	1.0	0.1	*	*	0.1	*	*	0.1	0.1
Kinase inhibitors	Trastuzumab		Asian	1.0	0.1	0.0	*	0.2	*	*	0.1	0.1
Kinase inhibitors	Trastuzumab		Hispanic	1.1	0.2	*	0.0	0.2	*	*	0.1	0.1
Kinase inhibitors	Trastuzumab		American Indian/Alaska Native	0.3	*	*	*	0.0	*	*	*	*

Table 5. Proportion of FFS Drug Users With a 200.x-208.x Cancer Diagnosis in 6-Month Window Prior to First Fill for Rituximab, Imatinib, and Lenalidomide (separately) by HRR, 2006-2009

Note: An asterisk (*) signifies a small cell count (less than 11).

HRR	Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim		
	Rituximab	Imatinib	Lenalidomide
1	88.7	67.0	73.1
2	82.8	*	100.0
5	88.3	100.0	75.9
6	82.0	63.6	86.2
7	92.9	*	75.0
9	68.5	*	*
10	80.6	93.3	84.6
11	75.9	82.4	85.7
12	85.8	75.8	80.0
14	83.1	*	78.6
15	79.8	52.2	77.8
16	88.3	63.2	*
18	86.6	94.1	81.3
19	87.1	54.5	73.3
21	87.3	57.9	68.4
22	88.5	*	85.0
23	81.7	58.3	71.3
25	78.5	74.1	*
31	94.2	*	73.1
33	82.2	*	78.3
43	82.3	74.2	80.0
56	78.5	59.3	76.2
58	79.0	59.4	78.1
62	84.4	*	86.7
65	76.9	77.3	82.4
69	81.4	*	71.9
73	80.8	70.6	81.3
77	81.8	64.7	89.0
78	89.7	*	87.0
79	76.2	78.9	87.8
80	79.0	59.0	82.3
81	89.1	64.0	75.9
82	87.8	63.2	93.5
83	84.0	*	*
85	84.2	*	90.0
86	83.3	*	85.7
87	74.6	*	61.1
89	87.0	*	65.0
91	76.2	*	*
96	85.5	78.3	68.4
101	80.5	*	*
102	76.4	*	76.9
103	83.7	74.4	81.8
104	82.8	*	100.0
105	86.0	*	*
106	81.8	*	85.0

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
107	61.5	*	*
109	77.6	57.7	84.3
110	90.0	58.3	85.4
111	87.2	67.3	78.4
112	87.3	70.7	90.0
113	83.3	52.8	82.2
115	84.8	*	69.6
116	78.5	79.3	62.1
118	82.7	60.6	73.9
119	88.2	70.8	75.6
120	90.8	60.0	73.0
122	91.3	*	71.4
123	83.7	73.0	83.0
124	96.7	75.0	88.9
127	60.8	65.6	73.8
129	93.1	67.6	73.7
130	86.8	66.4	78.7
131	91.0	68.8	71.9
133	80.3	*	*
134	90.0	65.0	86.2
137	85.0	70.8	74.0
139	83.6	78.6	95.0
140	78.2	87.5	80.0
141	86.6	64.7	84.8
142	85.8	*	100.0
144	80.7	63.6	80.7
145	83.8	60.9	81.5
146	78.1	*	*
147	77.9	71.0	62.8
148	86.2	*	75.0
149	84.8	76.7	88.1
150	86.3	44.4	87.5
151	70.3	*	84.6
152	84.5	*	*
154	86.0	*	*
155	86.3	72.0	78.4
156	86.8	61.1	88.7
158	86.9	72.2	84.6
161	87.8	73.5	78.4
163	89.1	*	80.0
164	88.0	77.8	66.7
166	88.6	78.6	77.6
170	89.4	62.1	68.6
171	86.0	66.7	67.5
172	88.4	82.2	75.3
173	92.6	85.0	92.0
175	88.3	*	73.3
179	87.7	93.1	81.0
180	89.0	73.1	83.9
181	81.4	*	75.0

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
183	85.3	64.6	72.0
184	90.1	*	*
185	95.0	*	*
186	82.9	*	88.2
187	89.5	63.0	79.6
188	81.4	84.6	*
190	83.2	*	*
191	79.8	66.7	82.1
192	88.8	58.1	83.3
193	87.9	*	*
194	85.8	*	72.2
195	86.1	*	*
196	90.5	*	*
197	88.0	*	75.0
200	84.1	*	95.8
201	88.2	66.7	83.7
203	86.9	64.7	81.0
204	88.6	71.4	79.7
205	83.7	74.5	79.8
207	83.0	*	*
208	90.7	73.7	74.1
209	81.5	*	71.4
210	85.9	81.1	87.0
212	92.0	92.3	92.3
213	85.5	72.0	82.1
214	90.9	*	*
216	91.8	*	60.9
217	69.4	*	85.7
218	86.4	*	70.6
219	80.6	67.9	88.6
220	96.0	*	*
221	80.9	*	80.0
222	78.9	54.8	82.7
223	85.1	62.7	81.4
225	83.7	64.7	76.5
226	80.4	*	84.0
227	83.4	64.9	83.7
230	79.4	52.2	76.5
231	83.4	82.4	71.4
232	81.1	80.0	82.9
233	88.9	*	81.0
234	81.3	53.1	83.1
235	87.1	78.9	85.7
236	86.1	62.5	91.2
238	81.1	65.2	89.7
239	81.3	63.2	83.3
240	84.5	*	*
242	86.5	*	91.7
243	66.4	*	92.3
244	87.3	*	85.0

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
245	88.0	78.6	82.6
246	87.7	76.2	85.7
248	88.3	*	*
249	88.5	*	84.0
250	82.6	*	77.3
251	84.1	67.9	79.6
253	82.4	75.0	78.1
254	77.8	*	82.4
256	84.0	76.0	82.4
257	85.4	*	*
258	83.2	*	83.3
259	78.7	53.6	87.2
260	85.6	*	100.0
261	75.9	*	*
262	86.3	50.0	68.4
263	83.6	*	81.8
264	85.5	67.9	84.1
267	87.1	*	63.2
268	88.5	66.2	87.2
270	82.8	73.3	74.2
273	82.4	64.6	81.4
274	78.3	77.3	79.3
275	81.7	*	*
276	85.8	*	87.5
277	82.7	54.2	74.1
278	87.0	66.7	76.4
279	89.4	68.8	69.2
280	83.3	*	72.0
281	77.7	77.3	74.2
282	81.8	65.0	87.2
283	88.3	64.3	77.4
284	82.7	57.4	79.0
285	89.1	65.6	85.5
288	89.0	63.6	64.6
289	85.8	52.6	85.1
291	82.7	*	90.9
292	85.4	*	88.5
293	70.1	62.5	79.5
295	86.7	65.5	75.7
296	91.6	*	82.1
297	83.5	64.4	92.1
299	80.3	78.6	83.3
300	94.5	87.5	*
301	84.1	67.2	87.4
303	85.3	57.9	83.0
304	87.9	57.1	88.2
307	91.7	66.7	85.7
308	92.3	70.5	85.3
309	84.5	80.0	77.8
311	76.6	74.3	81.3

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
312	85.0	76.0	86.5
313	86.2	72.7	77.8
314	83.6	85.3	73.5
315	79.5	*	78.9
318	79.5	57.9	78.2
319	80.5	78.3	92.6
320	86.7	68.2	84.1
321	85.9	*	65.0
322	85.9	85.2	81.1
323	81.9	*	71.4
324	81.6	*	*
325	91.5	*	*
326	85.2	86.4	73.1
327	87.8	68.6	83.8
328	86.9	62.0	80.7
329	84.1	79.2	74.5
330	90.4	67.6	77.4
331	84.5	*	*
332	89.6	*	*
334	89.9	73.3	70.3
335	87.7	71.4	81.8
336	93.5	*	73.3
339	88.3	66.2	82.0
340	83.0	66.7	82.8
341	64.6	*	100.0
342	89.3	63.6	82.6
343	85.3	70.6	73.1
344	86.4	67.5	76.1
345	84.2	*	*
346	89.3	71.0	73.9
347	84.6	*	*
350	90.7	*	75.0
351	87.2	62.5	84.6
352	90.6	77.4	79.6
354	90.0	*	*
355	89.2	*	93.9
356	83.2	67.9	75.1
357	90.6	75.0	74.3
358	86.1	68.8	90.5
359	87.9	*	92.3
360	83.5	*	100.0
362	90.0	73.7	77.3
363	92.8	60.9	78.8
364	80.2	67.9	63.6
365	78.7	69.4	85.9
366	83.3	51.2	75.0
367	60.5	69.6	78.4
368	86.7	47.5	77.6
369	82.7	*	94.4
370	68.8	*	*

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
371	86.7	75.9	88.5
373	79.5	68.1	74.0
374	92.5	*	76.7
375	88.0	*	91.7
376	82.8	84.0	76.5
377	86.2	62.3	82.6
379	85.7	71.6	78.3
380	87.7	70.8	85.6
382	88.0	*	73.3
383	81.7	*	83.3
385	83.5	77.8	83.3
386	91.2	56.5	96.7
388	85.7	*	*
390	82.5	87.5	73.7
391	84.1	70.6	82.0
393	90.3	65.7	70.7
394	87.4	64.1	87.0
396	85.1	63.6	86.4
397	87.0	71.4	86.7
399	87.0	87.5	100.0
400	83.6	82.6	80.0
402	86.1	85.0	*
406	89.4	83.3	94.1
411	96.0	*	*
412	82.3	64.2	71.4
413	88.3	*	*
416	81.7	80.0	77.8
417	94.0	*	84.6
418	91.9	*	*
420	84.6	*	82.6
421	77.4	*	*
422	88.6	*	*
423	83.4	71.4	75.0
424	73.5	*	81.3
426	87.1	75.0	80.6
427	80.5	73.9	83.0
428	83.5	*	*
429	82.8	*	74.1
430	83.5	54.8	78.9
431	86.0	58.0	83.7
432	88.3	72.7	86.6
435	75.2	*	91.7
437	88.4	*	93.3
438	89.5	*	*
439	83.4	69.8	80.9
440	80.9	80.0	79.5
441	81.4	77.3	80.6
442	75.6	85.7	*
443	88.3	81.0	70.5
444	91.9	*	84.2

Percentage of Beneficiaries with 200.x-208.x Cancer Diagnosis in Period of Continuous Enrollment Prior to First Relevant Claim			
HRR	Rituximab	Imatinib	Lenalidomide
445	89.2	80.0	86.4
446	84.0	*	*
447	79.2	*	79.2
448	86.2	*	93.3
449	78.6	70.0	92.9
450	87.4	*	*
451	83.5	74.2	78.2
452	83.0	*	*
456	82.4	*	*
457	79.7	*	*